

Delivering on Canada's genomics missions

2025–2026 Annual Report



Table of contents

**Joint message from the
President and the Board Chair _____ 4**

How we work _____ 6

Genome Canada by the numbers ____ 7

2025–26: A year of impact _____ 8

Precision health _____ 9

Agriculture and food _____ 11

Natural resources
and the environment _____ 14

Commercialization
and adoption _____ 17

Organizational excellence _____ 21

Operating challenges _____ 22

Looking ahead to 2026–27 _____ 23

Operations _____ 24

Governance _____ 24

Financial management _____ 26

Appendices _____ 28

Active projects
funded 2025–26 _____ 28

Auditors report and
audited financial statements _____ 55


Acknowledgements _____ 69

Genome Canada's main office is located on the unceded traditional land of the Algonquin Anishinabe Nation.

As a national organization, we support activities taking place on the traditional territories of many First Nations, Inuit and Métis peoples across the country.

We recognize past and ongoing injustices perpetrated against Indigenous peoples as part of the colonial project in Canada, including violence, oppression, land theft and harmful attempts to erase culture. Given Canada's colonial foundation and how it shapes the discourse and practice of science—especially genomics and related health and biomedical research—Genome Canada commits to fostering Indigenous truth, reconciliation and engagement in our programs to address the gaps in the participation of underrepresented, equity-deserving and Indigenous groups in Canada's genomics research agenda, data sets and governance.

Genome Canada commits to working in co-creative partnership with Indigenous researchers, leaders and communities to develop and support a stand-alone and distinctions-based strategy to bolster Indigenous genomics leadership in Canada.



Joint message from Genome Canada's President and Board Chair

Genome Canada is delivering on its mission to translate this country's genomics strengths into national priorities and tangible impact. This annual report shows that shift in action: missions moving from design through delivery, and from research to real-world outcomes that strengthen every corner of our country.

Following the launch of the [Canadian Genomics Strategy](#) in February 2025, we activated 38 new industry-academic R&D projects—the first phase of investments to accelerate the commercialization and adoption of genomics technologies across Canada. This represents over \$26 million in Genome Canada funding and more than \$57 million in co-investment, reflecting strong alignment with partners across the country.

Genome sequencing is now underway for the [Canadian Precision Health Initiative](#) (CPHI), launched in March 2025. Our largest initiative to date, CPHI will ultimately build a national databank of more than 100,000 human genomes in just four years, a valuable sovereign resource to support more precise, predictive and preventative health care.

Beyond its impact on health, CPHI reflects a broader reality. In a period of rising geopolitical volatility and uncertainty, developing made-in-Canada solutions and infrastructure for critical systems like health care is a strategic imperative. Canada's competitiveness, including its ability to lead in AI, will depend on its capacity to generate and steward [high-quality, sovereign data](#) at scale. The data emerging through CPHI represents a foundational national asset: [enabling health solutions](#) tailored to Canada's population while also offering globally relevant insights, given the country's genetic diversity.

In parallel, we advanced our mission in agri-food systems, with year three of the [Climate-Smart Agriculture and Food Systems](#) initiative, strengthening data coordination and knowledge sharing across research teams and the broader sector. We also progressed the design of our next major initiative to modernize how Canada manages and protects its natural resources—using genomics to generate and mobilize the data needed for more sustainable, resilient and economically competitive resource sectors.

All of these initiatives include support to advance Indigenous-led data governance and research priorities, recognizing the importance of supporting innovation in ways that reflect and uphold diverse knowledge systems and leadership. Effective governance is essential to developing effective, impactful mission-driven work and we will continue working with Indigenous partners and others to ensure we get governance right.

The challenges Canada faces—global uncertainty, supply chain disruption, economic and climate instability—require new sources of national strength and resilience. Through these missions, Canada's genomics community is generating concrete solutions: strengthening health systems, supporting food security and enabling more sustainable natural resource management while igniting new economic potential across sectors.

Our work underscores a fundamental shift. Science and technology are not only instruments of discovery—they are strategic national assets. The choices we make in how we develop and deploy them will shape Canada's prosperity, stability and competitiveness for generations.



Rob Annan
President and CEO



Bonnie Schmidt
Board Chair



How we work

Genome Canada translates genomics-driven biotechnology breakthroughs into transformative health, economic and environmental solutions for Canadians.

Our vision

We envision Canada as a global leader in biotechnology innovation and adoption.

Our work

To achieve our vision for Canada, we:

 Lead large-scale, mission-driven genomics initiatives that translate research into real-world impact.

  Build Canada's genomics capacity through strategic investments in research, technology and talent.

   Connect industry, academia and government in powerful cross-sector alliances—aligning federal, provincial and private-sector investments to amplify Canada's genomics impact nationally and globally.


What sets Genome Canada apart

We combine mission-driven, challenge-based program design, deep scientific expertise, and unparalleled convening power to transform genomics from laboratory discovery into commercial, social and environmental benefits for Canadians.

Through the Canadian Genomics Enterprise, which includes the six regional Genome Centres, we provide national coordination and locally responsive implementation. This distributed model allows Genome Canada to leverage federal funds and secure regional investment from provincial governments, industry, universities and non-profits through the Genome Centres. We work closely with the Canadian government and other federal science, technology and innovation ecosystem partners to address national priorities that align with regional needs, realities and strengths. We work in partnership across sectors and borders to drive investment and to coordinate, connect and diversify genomics research, innovation, data and talent initiatives to meet today's biggest challenges.

We have charted our course by addressing challenges in key priority areas—health, agriculture, natural resources and the environment, and commercialization—while also committing to organizational excellence in the pursuit and delivery of our work..

Genome Canada by the numbers



Number of projects for 2025-26 by region

Genome Atlantic	17
Génome Québec	36
Ontario Genomics	64
Genome Prairie	17
Genome Alberta	24
Genome British Columbia	33

Funding by sector

 \$23M Agriculture	 \$5.9M Environment	 \$49.1M Health
 \$0.8M Forestry	 \$1.3M Fisheries	 \$1.9M Technology platforms

2025–26: A year of impact

We are on a mission to strengthen Canada's global leadership in biotechnology innovation and adoption in order to ensure a healthier, more prosperous and sustainable future from coast to coast to coast. Our large-scale genomics initiatives, strategic investments and unique connecting power across regions will get us there.

To target our work in areas of greatest opportunity, we work with communities and with our partners to assess emerging trends, technological advances and societal needs to identify areas where research can make the biggest difference. These analyses involve careful consideration of market demand, scientific feasibility and innovation potential. We actively engage with industry partners, government agencies and academic institutions to leverage resources and expertise and maximize the effectiveness of our investments. And we are committed to the principle of inclusive genomics: we strive to ensure that our projects reflect Canada's diverse populations and that all benefits are equitably shared.

Explore the areas we prioritized in fiscal year 2025–26 and find out how we worked to address them. Funded through multiple contribution agreements, including the Canadian Genomics Strategy and the Strategic Science Fund, the initiatives described in this report demonstrate our impact for Canada over the past year.

Canadian Genomics Strategy delivery milestone

In 2025, Genome Canada activated 38 new industry–academic R&D projects to accelerate the commercialization and adoption of genomics technologies across the country. This is the first phase of a multi-year investment through our [Genomic Applications Partnership Program](#), supported by the [Canadian Genomics Strategy](#).



March 18, 2026 | Calgary, AB | Karim Bardeesy, Parliamentary Secretary to the Minister of Industry, announces federal investment in genomics R&D through Genome Canada.



Precision Health

Improving personal, community and population health while paving the way for precision health

In 2025–26, Genome Canada invested approximately \$48.2 million in research funding to support health projects. These projects are accelerating the clinical adoption of genomics across Canada, fostering innovative collaborations with clinicians and health care providers, developing new tools and practices for a range of medical conditions, and generating large-scale datasets that enhance researchers' abilities to apply genomic technologies effectively.

We convened national and global coalitions to strengthen genomics infrastructure initiatives.

- + We strengthened collaboration among Canadian and international researchers, institutions and industry partners by establishing a health genomics coalition and championing Canada's voice in international genomics initiatives.

We convened a genomic platforms mapping analysis with funding members from the Natural Sciences and Engineering Research Council of Canada, the Canada Foundation for Innovation, the Canadian Institutes of Health Research (CIHR), National Research Council Canada, the Digital Research Alliance of Canada, Canada's Drug Agency, and the Children's Hospital of Eastern Ontario. This analysis supports the development of a coordinated, accessible and sustainable national genomics data infrastructure that aligns with national priorities for data sovereignty, interoperability, precision health care, and global collaboration. The result is the coordination of the country's rich genomic resources under a shared national strategy. Of interest, this project has already contributed to the work of the Collaboratorium Asset Map & Gap Analysis Working Group, a Canadian Institute for Health Information initiative that aims to map health data resources into a national framework to guide system-level decisions.

- + We also assumed a prominent role on the world stage by participating in [Global Alliance for Genomics and Health \(GA4GH\) Connect](#) working sessions and [plenary meetings](#). As an active supporter of the 13th GA4GH Plenary Meeting, Genome Canada showcased Canada's leadership in setting worldwide standards for genomic data-sharing as outlined in the [Canadian Genomics Strategy](#). By engaging in GA4GH's high-profile forums, we have fostered partnerships with leading genomics companies, research bodies and large-scale genomic initiatives around the globe, reinforcing ties that will accelerate the creation and adoption of new data-sharing tools.

+ We continued to bring a unified view of the Canadian health genomic ecosystem to the National Initiatives Forum, which brings together national genomics programs to share best practices and advance standards for genomic data-sharing. Our coordinated engagement has helped organize the ecosystem, align national voices, and shape the standards, frameworks and mechanisms we need for national efforts, such as the CPHI and Collaboratorium.

+ We also convened two joint Canada–Australia workshops with [Australian Genomics](#) that brought together international leaders across the research, industry and health-care sectors. These workshops identified opportunities to strengthen the [collaboration with Australia](#) established in 2025 and explored pathways to implement and commercialize genomic medicine.



Canada's Michael Smith Genome Sciences Centre at the Provincial Health Services Authority in Vancouver, British Columbia.

+ Canada's growing investment in precision medicine and environmental genomics is creating massive amounts of data, but fragmented systems and uncoordinated standards hamper secure storage, sharing and analysis. To address this challenge, we funded programs under the CPHI and the [eDNA \(environmental DNA\) surveillance initiative](#) to support data programs that manage, govern and analyze CPHI data. The [Pan-Canadian Genome Library](#), a national initiative supported by CIHR, works with CPHI to develop a sovereign national asset of human genomic data and support data mining and access. We also supported DNASTack—a Canadian company with AI-powered software that securely manages and analyzes genomics data—to validate a made-in-Canada solution that fully integrates GA4GH standards to ensure safe and equitable access to CPHI data.

We supported national bioinformatics training and community capacity development.

+ Canada's life sciences sector faces challenges when it comes to meeting the demand for experts in bioinformatics, computational biology and data science. Researchers and institutions need accessible training, improved networks and ways to share knowledge in these rapidly developing fields. Building on a long-standing partnership with CIHR to develop highly qualified computational science talent, the [Canadian Bioinformatics Hub](#) (CBH) is addressing this gap by advancing skills development across Canada. The platform is built on two foundational pillars: training and community engagement. The hub delivers training programs and community resources tailored to local needs through six centres across Canada, helping to expand talent and expertise nationwide. Together, these efforts are strengthening Canada's health and life sciences sector by growing national capacity in the necessary areas of expertise.

+ With support from CIHR, the hub trains highly qualified personnel in computational biology and health data science. Over the past year, the CBH held 18 workshops in 7 cities across Canada and online on topics as diverse as the microbiome, spatial 'omics, RNA-seq analysis, and the R scripting language. Workshops like these further the goals of the training component of the [Canadian Genomics Strategy](#). In 2025, 266 trainees participated in these workshops, adding to the 5,000+ already trained by the CBH. Many more continue to access CBH's open access training content and recordings.

+ The CBH also laid the groundwork for its inaugural May 2026 conference, putting together a scientific program that combined career development sessions, expert-led learning, and networking opportunities in an inclusive environment. The CBH community grew, adding 16 organizations as Community Partners that will contribute to knowledge- and resource-sharing across Canada.



Agriculture and food

Building more resilient agriculture and food systems to boost economic productivity and safeguard environmental trust

Climate resilience in agriculture depends on generating and sharing bioinformatics data to allow farmers, researchers and policy-makers to advance climate-smart practices. In 2025–26, Genome Canada invested approximately \$23 million in the agri-food sector. We supported research innovations in the sector by contributing to resilient and sustainable food systems and farming processes, fostering strong collaborations with end users, and generating valuable proof-of-concept studies that show the potential of genomics to mitigate the impacts of climate change and ensure food security for Canadians.

In 2025–26, Genome Canada continued to support nine Interdisciplinary Challenge Team projects and two cross-cutting Hubs in the [Climate-Smart Agriculture and Food Systems](#) (CSAFS) portfolio.

We advanced tools and data to guide climate resilience practices.

- + Dairy farming contributes up to 1.4 per cent of Canada's total greenhouse gas emissions. To support the industry's commitment to achieve [Dairy Net-Zero](#) by 2050, Dairy Net-Zero (led by Ontario Genomics, Genome Alberta and Génome Québec) used genomics to develop Canada's first environmental impact genetic selection tool, including a methane-efficiency trait. Developed by researchers at the University of Guelph, Université Laval and the University of Alberta, the tool was adopted by industry and integrated into Canada's national dairy breeding index in 2025.
- + The [Climate Action Through Grazing](#) project, led by James Cahill (University of Alberta) and Carolyn Fitzsimmons (Agriculture and Agri-Food Canada and University of Alberta), used genomics to create practical indicators of soil and cattle microbiome health, helping ranchers make climate-smart grazing decisions that support carbon sequestration, rangeland health and efficient beef production.
- + CSAFS projects are generating and sharing data resources at a much-needed and unprecedented scale. For example, the [BENEFIT](#) project established the Canadian Collection of Agricultural Soil Microbes, generating thousands of microbial samples and genomes to support future bio-inoculant development, and the [PEAce](#) project produced the first field pea reference genome and sequenced 605 pea lines, providing important resources for plant breeders. Together, these datasets are advancing research and supporting innovation across Canada's agriculture sector.

We helped advance policy and best practices to address inequality.

- + Given that genomics technologies are developed and applied within broader social and economic systems, impacts on people and communities must be considered. Genome Canada's Interdisciplinary Challenge Teams generate evidence to inform policy and best practices. The [Just Transition](#) social sciences team completed studies examining agri-genomics and climate innovation in Canada, public perceptions of agricultural genomics, and the environmental impacts of emerging agri-food technologies. They also co-developed an Indigenous engagement toolkit to support more inclusive and equitable approaches to agri-tech innovation. These resources are helping policy-makers, industry and communities address social acceptance and equity considerations. Meanwhile, [BENEFIT](#) project data are informing the development of national quality and safety guidelines for bio-inoculants by collaborating with the CSA Group (formerly known as the Canadian Standards Association).

We led real-world innovations to demonstrate impact.

- + In 2025–26, many projects moved their innovations into real-world settings, engaging end users and demonstrating impact. The [Climate Action Through Grazing](#) project, for example, collaborated with ranchers to establish extensive on-farm grazing trials involving more than 400 hectares across more than 50 pasture sites in Alberta and Saskatchewan. Over two seasons, the project collected soil, plant and cattle samples and gleaned early evidence of increased soil carbon sequestration under climate-smart grazing regimes.
- + Likewise, the crop-focused [ACTIVATE](#) project engaged producers in field-based outreach, organizing demo field days and greenhouse gas workshops to showcase findings related to lentil–wheat rotation and discuss the adoption of low-carbon practices.
- + Across the portfolio, teams are involving stakeholders in the design and uptake of solutions. Notably, the [Just Transition](#) project formalized a Community Advisory Council with the Stó:lō Nation in British Columbia and created an Indigenous engagement toolkit to guide respectful collaboration. Several projects also held knowledge-sharing events (such as field tours, producer surveys and community fairs) to build trust and facilitate co-development, ensuring that genomics innovations are primed for uptake by farmers, industry and policy-makers.

We drove climate-smart innovation through knowledge-sharing.

- + There is a need to bridge the gap between cutting-edge genomics research and on-farm practices and policies. Genome Canada's dedicated knowledge mobilization hub for climate-smart agriculture, the [Agricultural Genomics Action Centre](#) (AG-ACt), facilitates cross-portfolio collaboration and training. The centre ensures that new innovations—from climate-resilient crops to low-carbon farming methods—can be easily understood and rapidly adopted by those who can use them, including producers, industry and decision-makers.



BENEFIT project researchers working on bio-inoculants for the promotion of nutrient use efficiency and crop resiliency in Canadian agriculture.

-
- + In 2025–26, a cornerstone of this effort was AG-ACt's [webinar program](#), which provided learning sessions to connect researchers and end users with knowledge and tools to implement genomics solutions. The webinars covered high-impact themes, such as creating effective scientific infographics, engaging Indigenous communities in agri-food research, and unpacking what climate-smart means in practice. The sessions introduced critical skills and insights for translating genomic innovations into real-world impacts. They were led by experts, such as an Indigenous engagement advisor who spoke about responsible collaboration and an expert from the Arrell Food Institute who taught data visualization. All webinar recordings were made freely available to maximize their reach and long-term value for Canada's agri-food community.

We fostered cross-disciplinary research collaboration.

- + The [Climate-Smart Data Collaboration Centre](#) established itself as a key coordinating data hub for the CSAFS portfolio, helping researchers share and use diverse data across disciplines. Working closely with all nine Interdisciplinary Challenge Teams, the data hub co-developed data standards, discovery tools and governance processes and provided tailored guidance on data management, privacy and integration. Through workshops, online platforms and collaboration with the AG-ACt hub, the data hub strengthened knowledge exchange across the portfolio and helped launch a unified [Climate-Smart Agri-Food Network](#) website, creating a single access point for tools, resources, training and project outcomes.

We explored how to improve resilience in the agri-food sector.

- + As environmental conditions continue to deteriorate, there is a need for livestock that can adapt to these changes while maintaining their productivity, health and fertility. A 2018 Large-Scale Applied Research Project led by the University of Guelph in partnership with UBC, Université Laval and the University of Alberta developed genomic tools and breeding indices that have been integrated into Canada's national dairy breeding framework. Adopted by industry, these tools are now [improving herd health, fertility and environmental performance](#) while providing the foundation for the [Dairy Net-Zero](#) commitment (described previously), focused on climate-resilient dairy production.
- + Honeybees are crucial to our country's agriculture, yet their health continues to decline. The [BeeCSI](#) project led by researchers at York University and UBC has developed and validated a genomics-based diagnostic platform to pinpoint the stressors affecting honeybee colonies. By integrating multiple 'omics data, the BeeCSI team produced practical diagnostic tools and management guidelines that have been adopted by Agriculture and Agri-Food Canada's National Bee Diagnostic Centre and are supporting pollinator health monitoring, crop production and food security.
- + Competition is stiff in global markets for agricultural exports. Canada, as the largest producer and exporter of lentils, seeks to take advantage of evolving market trends, such as the high-value food sector. Building on earlier investments in the [EVOLVES](#) project, the [ACTIVATE](#) project is applying advanced breeding, data and genomics tools to climate-smart lentil–wheat rotation and production systems. This work is helping Canadian growers improve their sustainability, meet evolving market demands, and strengthen their global competitiveness.



Natural resources and the environment

Boosting economic productivity while safeguarding Canada's forests, prairies, lakes and oceans

In 2025–26, Genome Canada invested approximately \$8.9 million in research funding to support projects in natural resources and the environment. These projects are strengthening Canada's ability to monitor, protect and restore ecosystems by supporting genomics research that informs conservation, biodiversity stewardship and climate resilience. By enabling data-driven environmental decision-making, these projects are helping to safeguard natural resources and support sustainable economic growth.

We pursued skills development and training for equity-deserving groups in the bioeconomy.

- + Indigenous communities in northern Canada, including Inuit, Cree and Dene, depend on fisheries for food security, recreation, cultural practices and livelihood. Climate change, shifting ecosystems and increased pressures from commercial fisheries threaten the sustainability of these vital resources. [FISHES](#), a 2018 Large-Scale Applied Research 2018 Project led by researchers at Université Laval, Concordia University and Carleton University, addresses this challenge by combining genomics knowledge with traditional ecological knowledge to better understand and manage six key fish species important to northern communities. By identifying genetically distinct fish populations, assessing climate vulnerability, tracking harvest contributions, and evaluating hatchery impacts, the project supports evidence-based, Indigenous-led fisheries stewardship. This co-developed approach is helping northern communities adapt to rapid environmental and socio-economic change.

We connected biodiversity initiatives to deliver coordinated genomic datasets and conservation outcomes.

- + Canada is home to nearly 80,000 plant and animal species, many of which are uniquely adapted to specific environments, from arid regions to the Arctic. Yet climate change and human activity are placing much of this biodiversity at risk. Without detailed genetic information, conservation efforts often lack the tools needed to monitor species health, manage populations and protect ecosystems effectively.

Key insights: Natural resources and biodiversity

Canada's natural resource and biodiversity sectors face growing pressures from climate change, ecosystem decline and intensifying global competition. Genomics can help—but its full potential remains untapped, and the genomic data we generate are fragmented, inconsistent and difficult to use. These obstacles limit our ability to manage ecosystems, monitor threats and unlock value.

But with stronger coordination, shared standards and the right infrastructure, genomics and AI can turn these data into actionable insights—positioning Canada to lead in sustainable resource management and environmental innovation. These insights are shaping Genome Canada's next national initiative in natural resources and biodiversity.

[Learn more here.](#)

+ As part of the international Earth BioGenome Project, the [Canadian BioGenome Project](#) brought together scientists, Indigenous Peoples, conservation groups and government organizations to sequence the genomes of approximately 400 Canadian species, generating high-quality genomic data for hundreds of species across terrestrial, freshwater and marine ecosystems. The project mapped genetic diversity to support biodiversity conservation, restoration and environmental stewardship. By coordinating efforts nationally and aligning data standards, it enabled researchers, governments and conservation organizations to access interoperable biodiversity data at an unprecedented scale.

+ These resources are now supporting climate adaptation planning, species conservation, and sustainable natural resource management. The project exemplifies Genome Canada's role in connecting biodiversity initiatives to deliver coordinated, nationally relevant biodiversity solutions. Key partners in this initiative included the Michael Smith Genome Sciences Centre, the University of Calgary, the University of Guelph, McGill University, Carleton University, the Hospital for Sick Children, the Royal Ontario Museum, and the European Bioinformatics Institute.

We convened leaders from Canada's natural resources and biodiversity sectors to identify priorities for genomics work.

+ To write the [Genomics for Canadian Natural Resources and Biodiversity](#) report, Genome Canada spent three years conducting research, consultations and cross-sector discussions to identify priorities and opportunities. This included convening virtual roundtables in January 2026 with stakeholders from Canada's biodiversity genomics and natural resource communities, alongside broader engagement with partners, Indigenous leaders, researchers and international initiatives. These discussions highlighted challenges related to standards, data governance and data-sharing while identifying opportunities for genomics to strengthen the sustainable management and competitiveness of Canada's natural resource sectors. The work also informed our commitment to continued engagement and investment in Indigenous-led solutions as we develop future natural resources initiatives.

Investing in eDNA monitoring

Environmental DNA is transforming how Canada monitors ecosystems, tracks emerging health threats, and protects key industries—providing faster, non-invasive insights into biodiversity, pathogens and environmental change. Genome Canada investments support projects across the country to build national capacity, strengthen data coordination, and enable more effective, evidence-based decision-making to safeguard Canada's health, environment and economy.

[Learn more here.](#)



Atlantic oyster farmers are using eDNA (environmental DNA) to help the shellfish industry bolster its defenses against major parasitic threats. Photo: PEI Aquaculture Alliance. +

Establishing strong Indigenous-led governance for Indigenous genomic data

Fostering Indigenous genomics stewardship

Many First Nations, Inuit and Métis communities want to ensure that the collection and use of genomics data reflect their governance, knowledge systems and priorities. An Indigenous-led microbial water safety project—a collaboration between the Atlantic First Nations Water Authority and the Centre for Water Resources Studies at Dalhousie University—aims to protect source water and provide wastewater surveillance. Programs using eDNA (environmental DNA) or RNA technologies, qPCR and next-generation sequencing are monitoring for microbes and viruses of interest. The project combines Indigenous knowledge with western approaches to improve water safety and stewardship.

First Nations-led disease surveillance

- + Rising temperatures are leading to the spread of disease vectors, such as ticks and mosquitoes. Health inequities, isolation and mistrust of health-care systems increase the risks for Indigenous communities. For remote First Nations, traditional medical testing can be intrusive, costly and impractical. To help address these issues, an eDNA surveillance program will provide wastewater and environmental monitoring and detection of avian-borne, vector-borne and zoonotic diseases. The project is a collaboration of First Nations communities in northern Ontario and other partners, including Environment and Climate Change Canada, the Canadian Food Inspection Agency, the Feather Board Command Centre, and the Ontario Ministry of Agriculture, Food and Agribusiness.

Indigenous genomic data sovereignty

- + In 2025, the Assembly of First Nations adopted Resolution #11 on genomic data sovereignty to address concerns about genomic data governance within the Canadian Precision Health Initiative (CPHI) and other genomic data programs. Genome Canada supports the need to move beyond colonial patterns of exploitative data extraction. We promote Indigenous data sovereignty, formal consent processes, and alignment with the OCAP® (ownership, control, access, possession) principles and United Nations Declaration on the Rights of Indigenous Peoples.

Genome Canada has published a statement on Indigenous data governance in the Canadian Precision Health Initiative. The statement reflects our ongoing efforts to strengthen how the initiative addresses and upholds Indigenous data sovereignty, including through distinct data-sharing options for Indigenous participants in CPHI projects. It provides more clarity on CPHI's governance frameworks and Genome Canada's commitment to support Indigenous genomic data frameworks.



Water sampling for a partnership advancing First Nations-led eDNA monitoring. Photo: Centre for Water Resource Studies.



Commercialization and adoption

Leveraging genomics to transform Canadian industry so homegrown companies are among the world's most innovative and productive

Canada's genomics sector has world-class research strength, but too many discoveries fall short of reaching patients, farms or industry. High development costs, fragmented partnerships and limited pathways to scale have made commercialization challenging, putting economic value, skilled talent and Canada's global competitiveness at risk. Through investments¹ in health, agriculture and natural resources, Genome Canada is helping translate genomics research into real-world applications that generate health, economic and societal benefits.

Genome Canada's [Genomic Applications Partnership Program](#) (GAPP) funds collaborative R&D projects between academic researchers and industry partners to advance commercialization and support public-private innovation. [Relaunched in 2025](#) with a stronger commercialization focus, the program was expanded in 2026 to allow up to 20 per cent of Genome Canada funding to flow directly to receptor organizations, with updated eligibility and funding requirements reflecting this change. GAPP includes both a national funding stream, with projects eligible for up to \$2 million, and regional streams administered through Genome Centres, with varying project envelopes.

We supported diverse projects across the health, agriculture and environment sectors by teaming up with public- and private-sector partners.

+ BIOREMEDIATION. BTEX compounds—benzene, toluene, ethylbenzene and xylenes—contaminate groundwater not only during oil spills and leaks, but also when oil is extracted, transported and refined. Clean-up is urgent, especially for benzene, which is carcinogenic. Yet remediation often requires costly excavation and offsite treatment.

To that end, a [GAPP bioremediation partnership](#) between the University of Toronto and SiREM, Inc. achieved the commercial scale-up of a bioremediation technology for petroleum contamination. In 2025–26, its "Field Validation of Anaerobic Benzene Bioremediation" project successfully demonstrated bioaugmentation with hydrocarbon-degrading microbial cultures at multiple field sites. The partnership commercialized DGG Plus, a proprietary bacterial culture that has been deployed at oil-contaminated sites across North America with support from Imperial Oil and other industry partners. This innovation not only helps remediate polluted soil and groundwater, but showcases how Canadian experts leveraged genomics to create marketable clean-tech solutions for environmental challenges. This success led the team to another promising GAPP project in 2026: a partnership with Federated Co-operatives Limited to deliver the first validated genomic framework to quantify and monitor anaerobic hydrocarbon biodegradation.



University of Toronto and SiREM researchers developing microbial solutions to [clean up toxic groundwater contamination](#).

¹ The dollar value of Genome Canada's 2025–26 funding for commercialization-focused projects is captured within the investments in the health, agriculture, and natural resources and environment priority areas highlighted in the first half of the report. The work we fund is translating genomics research into commercialization and adoption, spanning health, economic and societal benefits.

-
- + **BIOENGINEERING NYLON.** Because most nylon is still produced from petroleum, its production generates significant greenhouse gas emissions. As industries search for cleaner alternatives, demand is growing for nylon produced using synthetic chemicals derived from sugar. A GAPP project to [engineer bio-nylon](#), led by researchers at the University of Toronto and biotech start-up Visolis Inc., pioneered a sustainable materials breakthrough: engineering microbes to produce bio-based nylon. In 2025–26, the team developed novel genetic biosensors and spun out a new company, *OzoneBio*, to scale up the production of renewable bio-adipic acid—a precursor for bio-nylon—in partnership with Lululemon Athletica. This industrial biotechnology innovation is accelerating the commercialization of plant-based, low-carbon materials for the Canadian and global textile markets.
-
- + **DRUG DISCOVERY.** Many diseases, including cancer and inflammatory bowel disease, are linked to dysregulation of the human microbiome, yet scientists still understand little about the therapeutic potential hidden within these microbes. In 2025–26, a GAPP project led by researchers at [McMaster University in partnership with Adapsyn Bioscience](#) achieved a breakthrough in microbiome-based drug discovery. The team combined McMaster's world-class expertise in culturing human gut microbes with Adapsyn's AI-driven genomics platform to search for novel immune-regulating molecules from gut bacteria. The partners developed new methods to culture previously unculturable gut bacteria and sequence their genomes, then built a first-of-its-kind biobank of approximately 5,000 gut microbial isolates from 40 diverse Canadian donors. Each strain was fully sequenced, and the team identified hundreds of novel gene clusters linked to potential therapeutic molecules. These genomics-driven discoveries allowed Adapsyn's software to pinpoint promising new chemical compounds produced by the microbiome and test them for immune-modulating effects.
-
- + **CANCER SCREENING.** Ovarian and endometrial cancers are among the deadliest cancers affecting women, in part because by the time they are detected (often in stages III and IV), the disease has metastasized beyond the reproductive organs. A GAPP partnership between Optilab and the McGill University Health Centre (MUHC) seeks to change that. The [DOvEEgene](#) project delivered the first clinically validated, genomics-based screening test that can detect endometrial cancer and aggressive ovarian cancer subtypes in a real-world population of women in perimenopause or menopause.
-

Genomics, data and Canada's AI advantage

Genomics and AI are converging to transform how Canada solves complex challenges—from improving health outcomes to strengthening food systems and resource management. Together, these forces are turning biological data into a powerful driver of innovation, economic growth and national resilience. Genome Canada's white paper, titled *Genomics, the Digitization of Biology, and Canada's AI Opportunity*, explores how this convergence positions Canada to build a strategic advantage through high-quality, sovereign data and coordinated investment.

[Learn more here.](#)



*The AI-powered ClarityDX test uses blood-based biomarkers to improve prostate cancer detection and reduce health-care costs. (Commercialization and adoption project funded through the Canadian Genomics Strategy).
Photo: Nanostics Precision Health*

The core innovation combines a minimally invasive uterine sampling device, high-sensitivity DNA sequencing, and a machine-learning classifier to identify tumour-specific genetic changes and inherited cancer risk from a single test. Clinical trials demonstrated 75 per cent overall sensitivity and approximately 98 per cent specificity for detecting endometrial and ovarian cancers, including high-grade ovarian cancer, which is typically missed by existing screening approaches. In parallel, pathogenic hereditary cancer mutations were identified in approximately 1 per cent of participants. Access to this information allows preventive counselling and risk management for patients and their families.

A major outcome of the project was the successful translation of the assay into the Optilab-MUHC Clinical Genetics Diagnostic Laboratory, where clinical-grade workflows, quality-assured reporting, and automated bioinformatics pipelines were established and validated, thereby demonstrating readiness for high-throughput clinical implementation and laying the foundation for broader adoption and commercialization. Earlier detection could save thousands of lives, improve outcomes, and significantly reduce health-care costs across Canada.

-
- + GAMIFICATION.** Genomics research faces a major challenge: analyzing huge biological datasets takes time, is expensive, and requires significant computing power. Traditional bioinformatics struggles to keep up with the increasing complexity of microbiome and environmental genomics. What if researchers could gamify bioinformatics—essentially, harnessing online communities interested in citizen science to crowdsource solutions?

This is exactly what a GAPP partnership between McGill University, Massively Multiplayer Online Science (MMOS, a Swiss IT company), and Gearbox Studio Québec has delivered. Their groundbreaking citizen-science platform embedded real genomics research tasks into a major commercial video game—a [novel and scalable approach to engaging the public in microbiome research](#). By integrating the *Borderlands Science* mini-game into *Borderlands 3*, a blockbuster first-person action game, the team successfully crowdsourced sequence alignment solutions from more than four million players worldwide. Players generated nearly 150 million puzzle solutions, which were then used to construct a high-quality alignment of one million genetic markers (known as 16S rRNA sequences) used to identify bacteria.

These human-derived solutions outperformed traditional automated methods and allowed new insights into human gut microbiome variations associated with lifestyle and health factors. They also led to the development of machine-learning approaches trained on player behaviour. The result was a successful partnership between academic researchers, MMOS and Gearbox Studio Québec, which designed, deployed and promoted the game at global scale. This initiative not only advances microbiome research, but strengthens Canada's leadership in bioinformatics innovation and demonstrates how gaming communities can engage in citizen science and accelerate scientific discoveries.

-
- + CANNABIS BREEDING.** Canada's vibrant cannabis industry continues to expand, yet current cultivars remain vulnerable to powdery mildew and lack the agronomic traits needed for large-scale production. The [Fast-Track Breeding of Powdery Mildew-Resistant Cannabis](#) project established a genomics-enabled breeding platform for cannabis and successfully applied it to identify and deploy genetic resistance to powdery mildew. An academic–industry collaboration between Dr. Loren Reiseberg of UBC and Aurora Cannabis generated high-quality genomic resources, including 12 phased, chromosome-level cannabis genome assemblies and a large, well-characterized association mapping population of 500 cultivated cannabis lines.

By combining whole-genome sequencing, large-scale disease phenotyping, and genome-wide association analyses, the project identified both known and previously undiscovered genetic loci associated with resistance to powdery mildew, including a newly identified resistance locus known as *PM2*. Genetic markers for *PM2* were developed and integrated into Aurora's marker-assisted breeding pipeline. This allowed for the rapid introduction of durable powdery mildew resistance into elite cannabis cultivars that are now at advanced stages of assessment prior to commercialization. The project strengthened Canada's leadership in cannabis genomics, reduced the use of chemicals for disease control, and delivered a modern, genomics-driven breeding capability that is already making Aurora Cannabis more globally competitive.

We convened relevant leaders to identify opportunities to increase commercialization in genomics.

- + In September 2025, Genome Canada and Genomics Australia convened two Canada–Australia virtual workshops that brought together leading researchers, clinicians, industry representatives, policy-makers, patient advocates and interested government parties to advance collaboration and commercialization opportunities in genomics. The first workshop, *Optimizing the Value of Genomic Medicine*, focused on how to define, measure and scale the value of genomic medicine through system-level integration, interoperable data, equitable implementation and stronger cross-sector collaboration. The second, *Building Canada–Australia Collaboration Across Industry/Research Engagement and Partnerships*, focused on strengthening innovation pipelines for genomic health technologies by identifying opportunities for bilateral industry–research partnerships, addressing barriers to implementation and commercialization, and mapping complementary strengths between Canada and Australia.
- + Together, the workshops demonstrated Genome Canada’s role in convening relevant international leaders and cross-sector experts to align innovation ecosystems, foster strategic partnerships, and identify practical pathways to increase the adoption and commercialization of genomics. Insights from the workshops informed the March 2026 what-we-heard report, [*Genomics for Canadian Natural Resources and Biodiversity*](#).

Embedding inclusion and Indigenous engagement across our work

Inclusion, Diversity, Equity, and Accessibility (IDEA) and Indigenous Truth, Reconciliation, and Engagement (ITRE) are foundational to organizational excellence at Genome Canada. Grounded in the understanding that impactful genomic research requires diverse data, experiences and perspectives, we embed these principles across our design frameworks, community engagement and strategic initiatives.

- + To drive equitable, community-informed outcomes, all Genome Canada funding programs require applicants to meaningfully integrate IDEA and ITRE principles into their proposals. Teams must demonstrate concrete commitments across research design, methodology, team composition, and Indigenous engagement strategies as a condition of investment.
- + Furthermore, our Indigenous Engagement Charter guides our approach through five strategic pillars: knowledge translation, talent development, data rights and sovereignty, innovation transfer, and economic transformation. This structured approach ensures that our investments sustainably support Indigenous leadership and promote long-term benefit-sharing.
- + To assess progress since the launch of our IDEA strategy in 2023, we undertook a comprehensive retrospective review in 2025. Key achievements emerging from this review include the formal endorsement of the federal [50–30 Challenge](#), gains in project leadership by women, and a major Canadian Precision Health Initiative investment that supports Indigenous and Black health.
- + Throughout 2025–26, we continued to advance equitable hiring and recruitment practices to diversify our workforce and Board of Directors. By using inclusive language, employing diverse selection panels, and delivering unconscious bias and inclusive leadership training to managers, we strived to ensure that our workplace and governance structures reflect the communities we serve.

Organizational excellence

Strengthening organizational excellence is pivotal to delivering on our research priority areas. This means continuing to live our corporate values, foster a strong and healthy corporate culture, and use efficient processes and technologies to deliver exceptional work. Focusing on innovation, collaboration and excellence, we align our people, processes and technologies with our objectives and strategic directions.

Our ongoing digital transformation plays a central role in this alignment, driving enhancements in research security, cybersecurity, grant management and client relationship management. These improvements are helping us to streamline our operations, foster effective collaborations, and deliver positive experiences for everyone involved.

Research security

In 2025–26, we continued our commitment to research security in a rapidly evolving policy environment. Building on the December 2024 rollout of our Research Security Plan—which supports compliance with the Government of Canada’s 2023 [National Security Guidelines for Research Partnerships](#) and 2024 [Policy on Sensitive Technology Research and Affiliations of Concern](#)—we continued to apply our established processes, including attestation and risk assessment requirements and the related validation procedures. We also continued to work with our Canadian Genomics Enterprise partners, the federal granting agencies, the Canada Foundation for Innovation, and national third-party research organizations to support the ongoing implementation of updated security policies and procedures and to better integrate national security considerations into our activities.

Cybersecurity

In 2025–26, we continued to strengthen our cybersecurity readiness by reviewing our IT and cybersecurity policies and reinforcing secure practices across the organization. Employees participated in annual refresher courses, random monthly phishing simulations, and retraining if needed. Our cybersecurity plan, approved by Innovation, Science and Economic Development Canada, has been in place since August 2022.

Grant management

In 2025–26, we were in year two of our new, comprehensive, organization-wide grants management system, designed to enhance the efficiency of the funding application, review and post-award management processes for both Genome Canada and the regional Genome Centres. The system has now been used in nine funding competitions, processing a total of 104 applications (up from 76 the previous year). Over the past year, while building on efficiencies enabled by the system, we continued to refine our post-award procedures to strengthen how we track, understand and measure the impact of our funding.

Customer relationship management

In 2025–26, we expanded our use of a customer relationship management tool to strengthen how we manage relationships with key partners and collaborators. The tool is now widely adopted across the organization and tracks our interactions with priority audiences, including research portfolio teams and regional Genome Centres. To date, more than 16,000 interactions have been recorded. This past year, we migrated the sponsorship and membership tracking process into the customer relationship management tool. As a result, we can now readily track and report on engagements and gain deeper insights into our partner network year over year.

Operating challenges in 2025–26

Genome Canada is now funded via the Strategic Science Fund (SSF) announced in 2023 and the Canadian Genomics Strategy (CGS) announced in 2025. This arrangement provides stable, predictable, multi-year funding for genomics in Canada and allows Genome Canada and its partners to harness the national genomics ecosystem to address the major economic, environmental, health and social challenges of our time.

This year, to align ourselves with priorities of the Strategic Science Fund (SSF) and the Canadian Genomics Strategy (CGS), along with a revised multi-year funding profile in our active contribution agreements, we advanced a more efficient and impactful regional model, while continuing to evolve our strategic planning and operations. These shifts emphasize excellence in research, talent development, knowledge mobilization, commercialization, and stronger collaboration across Canada's genomics ecosystem to accelerate innovation and address critical health, environmental and economic challenges. We continued to realign our resources and worked closely with the regional Genome Centres to ensure the continued strength and sustainability of our collaborative model. Together, we are laying the groundwork for long-term impact.

Meanwhile, the SSF and CGS continued to expand their reporting and accountability requirements. While we fully support transparency and performance measurement, we are a lean organization, and these requirements place additional pressure on our limited operational capacity. In 2025–26, we continued to manage these responsibilities with diligence and professionalism while streamlining our administrative processes to meet the reporting requirements as effectively and efficiently as possible.

Overall, we have adapted to the SSF and CGS parameters and are making intentional, strategic decisions to maximize our future investments. Our stable, predictable funding model will allow us to move forward with certainty and focus over the next four years, as reflected in our [2025–2030 Strategic Directions](#) report.



2025-2030
Strategic Directions

Showing the world
what we're made of

Looking ahead to 2026–27

In 2026–27, Genome Canada will continue to deliver coordinated, large-scale impacts in precision health, natural resources, agriculture and food, and commercialization and adoption.

As Canada's genomics leader and a key delivery partner for the CGS, we will continue to work closely with the federal government, regional Genome Centres, and partners across the sector to drive commercialization through our evolving GAPP program and other innovative industry-focused programs. We will continue to coordinate the national ecosystem around data leadership, advance a national genomic research data strategy, and support the CGS in its work with industry leaders and international trade missions to strengthen Canada's global competitiveness and impact.

To support Canada's position in the global bioeconomy, we will continue to expand our commercialization programming through new GAPP rounds. These investments will drive collaboration between industry and academia, accelerate the adoption of genomics-enabled technologies, and support the growth of Canadian companies.

A key priority will be strengthening Canada's precision health ecosystem. As the CPHI moves into broader implementation, we will focus on mobilizing and applying genomic data. This work includes strengthening long-term data governance, including increased support for [Indigenous-led data governance](#) that upholds inherent rights to self-determination and sovereignty for Indigenous Peoples. We are also building the infrastructure to make data genuinely usable. That means investing in interoperability, standardized data models, and the secure systems researchers need to work across institutions and borders. Canada has spent years collecting data. The next phase will be about putting it to work: connecting it in ways that accelerate discovery and, eventually, better care.

We will also take steps to implement a new national genomics initiative focused on natural resources. This initiative will address long-standing fragmentation in biodiversity and non-human genomics data by aligning research, data standards and infrastructure across sectors. Ultimately, it will support coordinated decision-making, sustainable resource development, and stronger environmental monitoring capacity.

Looking ahead, we are formalizing a dedicated mission focused on genomics and its ethical, environmental, economic, legal and social aspects (GE3LS) to determine exactly what institutional, policy and societal conditions are needed to turn genomic discoveries into real-world impacts. By intentionally embedding GE³LS into our core framework, we can get ahead of adoption risks and build regulatory readiness. Ultimately, this approach is about bridging the gap between responsible science and the policy-makers, industry leaders and communities we need on board to deliver long-term national success.

Recognizing the federal focus on economic growth, innovation and industry competitiveness, we are working with numerous policy partners to strengthen the evidence base for the role that genomics and biotechnology can play in Canada's future. Together with policy leaders like the Public Policy Forum, the Canadian Chamber of Commerce, and Signal 49 (formerly the Conference Board of Canada), we are quantifying the contribution of genomics to Canada's economy today and modelling its potential across the emerging bio revolution. This work will inform future policy, investment, and decision making to bolster innovation and research in Canada.

Finally, we will continue to convene and connect Canada's genomics community across regions and globally. Through targeted engagements and strategic partnerships, we will bring together leaders from research, industry, government and communities to align our priorities, advance our missions, strengthen coordination and prepare for new challenges. Our next national genomics summit will be held in Ottawa in early 2027.

Together, these actions reinforce Genome Canada's role in delivering on Canada's genomics ambitions — aligning investments, partners and infrastructure to accelerate impact and strengthen Canada's resilience, sustainability and competitiveness.

Operations

Governance

Genome Canada is governed by a Board of Directors comprising up to 16 individuals from the academic, private and public sectors. Directors bring unique skills and experiences as well as strong interests and insights to help us carry out our strategic plan. Generally, a director is appointed for a two-year term and may hold office for a maximum of six consecutive years. Exceptions are the chair, who may hold office as director for a maximum of eight consecutive years, and the president and CEO, who is appointed annually but has no term limit as a director.


The board has overall responsibility for the stewardship of our business and affairs. To help with the discharge of these duties, the board has five standing committees:

- + Audit and Investment Committee
- + Communications and Outreach Committee (generally not active)
- + Executive Committee (generally not active)
- + Governance, Election and Compensation Committee
- + Programs Committee

Additionally, a Science and Industry Advisory Committee provides strategic advice.

Number of meetings held by the Board and its committees in 2025–26

Board of Directors	7
Audit and Investment Committee	4
Communications and Outreach Committee	0
Executive Committee	0
Governance, Election and Compensation Committee	4
Programs Committee	4
Science and Industry Advisory Committee	2



Board of Directors and Science and Industry Advisory Committee members in 2025–26

Board of Directors

Elizabeth Douville (Chair until June 2025)

President and Chief Executive Officer
IRICoR
Montreal, Quebec

Bonnie Schmidt (Vice-Chair until June 2025, Chair as of June 2025)

Founder and President
Let's Talk Science
London, Ontario

Deborah Buszard (Vice-Chair as of June 2025)

Principal Emerita
The University of British Columbia
Kamloops, British Columbia

Rob Annan

President and Chief Executive Officer
Genome Canada
Ottawa, Ontario

Jennifer Gardy

Deputy Director, Surveillance, Data & Epidemiology
Gates Foundation
Chicago, Illinois, U.S.
Until June 2025

Ivo G. Gut

Director
Centro Nacional de Análisis Genómico (CNAG)
Barcelona, Spain

Avak Kahvejian

General Partner
Flagship Pioneering
Cambridge, Massachusetts, U.S.

Ingrid Richter

Partner
Threshold Associates
Ottawa, Ontario

Cami Ryan

Senior Business Partner, Industry Affairs and Sustainability
Bayer CropScience Canada
Calgary, Alberta

Andrew Stephens

Corporate Director, retired oil and gas executive
Canmore, Alberta

Iain S. Stewart

Corporate Director
Ottawa, Ontario

Éliane Ubalijoro

Chief Executive Officer
Center for International Forestry Research (CIFOR) and International Centre for Research in Agroforestry (ICRAF)
Director General, ICRAF
Nairobi, Kenya

Colin Webster

Vice-President, Sustainability and External Affairs
Alamos Gold Inc.
Burlington, Ontario

Science and Industry Advisory Committee

Cami Ryan (Chair)

Senior Business Partner, Industry Affairs and Sustainability
Bayer CropScience Canada
Calgary, Alberta

Kristin Baetz

Dean of the Faculty of Science and Professor of Biological Sciences
University of Calgary
Calgary, Alberta

Erin Grey

Associate Professor of Ecological Bioinformatics
University of Maine, Maine Center for Genetics in the Environment
Orono, Maine, U.S.

Blake C. Meyers

Director, UC Davis Genome Center
Distinguished Professor, Department of Plant Sciences
Novozymes Chair of Genomics
University of California, Davis
Davis, California, U.S.

Sohrab Shah

Chief of Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center
Professor, Weill Cornell Medical College
New York, New York, U.S.

Jeremy Shears

Chief Scientist, Biosciences Shell
London, UK
Until June 2025

Joris Andre Veltman

Director, Institute of Genetics and Cancer
University of Edinburgh
Edinburgh, UK

Rae S.M. Yeung

Professor of Pediatrics, Immunology and Medical Science, University of Toronto
Staff Rheumatologist, The Hospital for Sick Children
Toronto, Ontario
Until July 2025

Management team

Rob Annan

President and Chief Executive Officer

Naveed Aziz

Chief Data Officer

Catalina Lopez-Correa

Chief Global Strategy Officer
Until January 2026

Dalia Morcos Fraser

Chief Operating Officer and Chief Financial Officer


Financial management

Since its inception in 2000, Genome Canada, along with co-funding partners, has invested approximately \$4.2 billion in genomics research and the operation of the six regional Genome Centres. Cumulatively, we provided approximately \$1.7 billion of this through our federal funding; the remaining \$2.5 billion has come from national and international organizations, including federal and provincial governments, post-secondary institutions, not-for-profit organizations, and private- and public-sector partners.

Most research projects require applicants to secure co-funding. Historically, our required co-funding ratio was \$1 in partner funding for every \$1 invested by Genome Canada. By the end of fiscal year 2025–26, partner contributions had increased to \$1.47 for every \$1 invested by Genome Canada, reflecting the continued strength of our partnership model.

Genome Canada receives annual funding from Innovation, Science and Economic Development Canada through active contribution agreements to support genomics research and initiatives across Canada, primarily through competitively selected academic and industry-led partnerships. In 2025–26, research funding was delivered through four active contribution agreements.

We work closely with the six regional Genome Centres to flow program funding, with the Centres overseeing project funding in their regions. Projects, which are administered through host institutions, also receive funding directly from co-funders. Genome Centres and project leaders report secured co-funding quarterly. This enables Genome Canada and the Centres to monitor total project investment.




In 2025–26, a total of \$139.6 million was invested in genomics research: \$91.4 million from Genome Canada and \$48.2 million from co-funders. Co-funding investments included:

- \$6.3 million from other federal sources
- \$17.4 million from provinces
- \$4.0 million from industry
- \$20.5 million from Canadian non-for-profit organizations and foundations, foreign governments, and foreign not-for-profit organizations

2025–26 Research funding supported by the Canadian Genomics Enterprise

- Genome Canada
- Other Federal
- Provincial
- Industry
- Universities, Canadian non-for-profit organizations, foundations, and foreign governments and not-for-profit organizations



As presented in the graph, a small portion of our federal funding is dedicated to supporting our operating costs, which were \$6.7 million in 2025–26. The increase in operating costs since 2024-25 results from additional operating funding provided through the CGS, starting in 2025–26, to lead the coordination and strategic planning of activities that will enhance data management and security, promote greater access to genomics datasets, and ensure that the data generated are made available for broad use, including technology adoption and commercialization.

Operations include activities relating to program management and oversight, strategy, external relations, communications, governance, and convening, engagement and networking. Some additional operating funding from the CGS was dedicated to the data initiative.

Approximately 60 per cent of our operating expenditures are allocated to salaries. Genome Canada's compensation framework includes job classifications and corresponding salary ranges for all roles. Employees are eligible for an annual performance award of up to 10 per cent of their base salaries. Vice-presidents (or those in equivalent positions) can receive up to 20 per cent, based on the achievement of annual objectives. For positions with salaries exceeding \$100,000 as of March 31, 2026, the annual ranges were:

- Directors: \$98,116 to \$189,392
- Executives: \$162,478 to \$243,718
- President and CEO: \$290,000 to \$390,000

Salary ranges are reported as of March 31 of the reporting year. In the prior year, the ranges reflected those in effect at the time of report preparation.

Active Project List 2025-2026

Large-scale science

LARGE-SCALE APPLIED RESEARCH PROJECTS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Alberta Ontario Genomics	Forestry	Cooke, Janice Cullingham, Catherine	University of Alberta Carleton University	TRIA-FoR: Transformative Risk Assessment and Forest Resilience Using Genomic Tools for the Mountain Pine Beetle Outbreak	\$6,431,135	\$2,999,994
Genome Alberta Génome Québec	Environment	Muench, Douglas Martineau, Christine	University of Calgary Natural Resources Canada	Application of Genomics to Enhance Wetland Treatment Systems for Remediation of Processed Water in Northern Environments	\$6,379,093	\$2,983,534
Genome British Columbia Génome Québec	Environment	Helbing, Caren Langlois, Valérie Dupras, Jérôme Bernatchez, Louis	University of Victoria Institut national de la recherche scientifique Université du Québec en Outaouais Université Laval	iTrackDNA: Non-Destructive Precision Genomics for Environmental Impact Tracking in a Global Climate Change Era	\$11,979,761	\$3,000,000
Genome British Columbia Genome Alberta	Agriculture	Jones, Steven Murray, Maribeth	BC Cancer Michael Smith Genome Sciences Centre University of Calgary	The Canadian BioGenome Project	\$6,294,530	\$2,999,963
Genome Atlantic	Environment	Frasier, Timothy Hamilton, Philip	Saint Mary's University New England Aquarium	Conservation Genomics of the Endangered North Atlantic Right Whale	\$6,020,874	\$2,119,435
Genome Prairie	Environment	Stern, Gary Collins, Eric	University of Manitoba	Reimagining Monitored Natural Attenuation as an Oil Spill Response Strategy in the Arctic	\$6,570,702	\$2,998,477
Ontario Genomics	Environment	Yang, Laurence Zechel, David DiCenzo, George McLellan, P. James	Queen's University	Optimizing a Microbial Platform to Break Down and Valorize Waste Plastic	\$7,675,843	\$3,000,000

LARGE-SCALE APPLIED RESEARCH PROJECTS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Environment	Hébert, Paul	University of Guelph	BIOSCAN–Canada	\$6,999,588	\$3,000,000
Genome Alberta Ontario Genomics Genome British Columbia Génome Québec	Agriculture	Baes, Christine Stothard, Paul Cerri, Ronaldo Sirard, Marc-André	University of Guelph University of Alberta The University of British Columbia Université Laval	Integrating Genomic Approaches to Improve Dairy Cattle Resilience: A Comprehensive Goal to Enhance Canadian Dairy Industry Sustainability	\$12,541,132	\$3,997,769
Genome British Columbia	Agriculture	Birol, Inanc	The University of British Columbia	PeptAid – Antimicrobial Peptides to Replace Antibiotics in Farm Veterinary Practice	\$6,887,638	\$3,441,747
Genome Prairie	Agriculture	Bett, Kirstin Vandenberg, Albert	University of Saskatchewan	Enhancing the Value of Lentil Variation for Ecosystem Survival (EVOLVES)	\$7,432,398	\$3,519,023
Genome Prairie Genome Alberta	Agriculture	Waldner, Cheryl Otto, Simon	University of Saskatchewan University of Alberta	Genomic ASSETS (Antimicrobial Stewardship Systems from Evidence-based Treatment Strategies) for Livestock	\$5,678,154	\$2,540,323
Genome Prairie Ontario Genomics	Agriculture	Pozniak, Curtis Cloutier, Sylvie	University of Saskatchewan Agriculture and Agri-Food Canada	4DWheat: Diversity, Discovery, Design and Delivery	\$11,166,747	\$4,044,856
Génome Québec Ontario Genomics	Fisheries	Bernatchez, Louis Moore, Jean-Sebastian Fraser, Dylan J. Schott, Stephan	Université Laval Concordia University Carleton University	FISHES: Fostering Indigenous Small-Scale Fisheries for Health, Economy, and Food Security	\$14,404,554	\$4,000,000
Ontario Genomics Genome British Columbia	Agriculture	Zayed, Amro Foster, Leonard	York University The University of British Columbia	BeeCSI: 'Omic Tools for Assessing Bee Health	\$9,922,052	\$3,831,866

LARGE-SCALE APPLIED RESEARCH PROJECTS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics Genome Prairie	Fisheries	Heath, Daniel Docker, Margaret Cooke, Steven J.	University of Windsor University of Manitoba Carleton University	GEN-FISH: Genomic Network for Fish Identification, Stress and Health	\$9,072,963	\$3,999,815
Genome British Columbia	Health	Arbour, Laura Caron, Nadine Wasserman, Wyeth W.	The University of British Columbia BC Children's Hospital Research Institute	Silent Genomes: Reducing Health-Care Disparities and Improving Diagnostic Success for Indigenous Children with Genetic Disease	\$13,399,812	\$4,200,000
Genome British Columbia Génome Québec	Health	Elliott, Alison M. Knoppers, Bartha Lynd, Larry Austin, Jehannine	BC Provincial Health Services Authority McGill University The University of British Columbia	GenCOUNSEL: Optimization of Genetic Counselling for Clinical Implementation of Genome-wide Sequencing	\$4,237,284	\$1,004,017
Genome British Columbia Génome Québec Genome Alberta	Health	Keown, Paul Sapir-Pichhadze, Ruth Caulfield, Timothy Bryan, Stirling	The University of British Columbia McGill University University of Alberta	Precision Medicine CanPREVENT AMR: Applying Precision Medicine Technologies in Canada to Prevent Antibody-Mediated Rejection and Premature Kidney Transplant Loss	\$10,834,538	\$2,036,000
Genome British Columbia Ontario Genomics	Health	Turvey, Stuart Kobor, Michael Finlay, Brett Subbarao, Padmaja	The University of British Columbia The Hospital for Sick Children	Childhood Asthma and the Microbiome - Precision Health for Life: The Canadian Healthy Infant Longitudinal Development (CHILD) Study	\$9,142,486	\$4,569,644
Ontario Genomics	Health	Ratjen, Felix	The Hospital for Sick Children	Personalized Therapy for Individuals with Cystic Fibrosis	\$9,488,508	\$4,999,907
Ontario Genomics	Health	Stintzi, Alain Mack, David	University of Ottawa Children's Hospital of Eastern Ontario	Microbiome-Based Precision Medicine in Inflammatory Bowel Disease	\$9,266,995	\$4,555,624
Ontario Genomics Genome Alberta	Health	Yeung, Rae S.M. Benseler, Susanne M.	The Hospital for Sick Children University of Calgary	UCAN CURE: Precision Decisions for Childhood Arthritis	\$10,000,000	\$5,000,000

LARGE-SCALE APPLIED RESEARCH PROJECTS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Environment	Lougheed, Stephen C. van Coeverden de Groot, Peter Whitelaw, Graham Dyck, Markus	Queen's University Government of Nunavut	BEARWATCH: Monitoring Impacts of Arctic Climate Change using Polar Bears, Genomics and Traditional Ecological Knowledge	\$9,219,247	\$2,708,282
Ontario Genomics Genome British Columbia	Forestry	Master, Emma Brumer, Harry	The University of Toronto The University of British Columbia	SYNBIOMICS: Functional Genomics and Techno-Economic Models for Advanced Biopolymer Synthesis	\$10,725,222	\$2,830,771

EMERGING ISSUES

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Atlantic	Health	Hatchette, Todd Ogden, Nicholas Lindsay, Robbin	Dalhousie University Public Health Agency of Canada	Lyme Disease in NS: The Influence of Strain Variation on Clinical Disease	\$780,801	\$242,800
Genome British Columbia	Health	Hieter, Philip	The University of British Columbia	Research Network: Expanding Collaboration between Basic and Clinician Scientists in Functional Studies of Novel Rare Diseases	\$1,679,500	\$560,000

REGIONAL, NATIONAL AND INTERNATIONAL INITIATIVES

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Health	Boycott, Kym Sommerville, Martin	Children's Hospital of Eastern Ontario Research Institute	Defining a Canadian Data Solution that will Deliver Precision Health for Rare Genetic Disease	\$1,250,000	\$1,250,000
Ontario Genomics	Health	Goodhand, Peter Joly, Yann	Ontario Institute for Cancer Research	Supporting Canadian Leadership in International Genomic Data Sharing Through the Global Alliance for Genomics and Health (GA4GH)	\$2,859,000	\$800,000
Genome Alberta	Health	TallBear, Kim Kolopenuk, Jessica	University of Alberta	Summer Internship for Indigenous Peoples in Genomics (SING) Canada	\$240,000	\$240,000
Ontario Genomics	Health	Brazas, Michelle Stein, Lincoln Bourque, Guillaume Hsiao, William	Ontario Institute for Cancer Research	Canadian Bioinformatics Workshop	\$537,860	\$247,059
Génome Québec	Health	Roy, Nicholas	McGill University	Testing the Presence and Genetic Predictors of Stronger Placebo Effect of Personalised Treatments	\$96,358	\$48,179
Genome Alberta	All	Chowdury, Tanvir	University of Calgary	Human Genomics and Racialized Communities: Identifying Strategies for Equitable Inclusion	\$30,000	\$30,000
Ontario Genomics	Health	Fook, Nicholas	University of Ottawa	Addressing Racisms and Anti-Racism in Science and Teacher Education Research	\$29,857	\$29,857
Génome Québec	Health	Joly, Yann	McGill University	Opportunity and Misuse of Genetic Ancestry Data in Biomedical Research: A Systematic Review of the Literature	\$29,966	\$29,966

REGIONAL, NATIONAL AND INTERNATIONAL INITIATIVES

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Alberta	Health	Limoges, Jacqueline	Athabasca University	Developing Equity Strategies for Genomics Informed Nursing (DESIGN): A Scoping Review	\$30,000	\$30,000
Genome Alberta	Health	Zheng, Yao	University of Alberta	Taking Stock and Moving Forward: Synthesizing Ethnic/Racial Diversity in Canadian Social Genomics	\$30,000	\$30,000
Ontario Genomics	Health	Bell, Jennifer	The University of Toronto	Personalized Genetic Drug Technologies and Medical Economies in Canada: Moral Experiment or Curative Renaissance?	\$199,462	\$99,731
Ontario Genomics	Health	Duggan, Ana	McMaster University	In Crypts and Cabinets: Uniting Ancient DNA and the History of Medicine to Re-examine the Emergence of Smallpox and the Advent of Vaccination	\$170,368	\$85,189
Genome Atlantic	Fisheries	Harrison, Hannah	Dalhousie University	Social and Cultural Narratives of Salmon Production, Conservation and Care	\$30,000	\$30,000
Ontario Genomics	Health	Brazas, Michelle	Ontario Institute for Cancer Research	The Canadian Bioinformatics, Computational Biology and Health Data Sciences Training and Community Platform	\$6,050,000	\$500,000
Génome Québec	Health	Bourque, Guillaume Zawati, Ma'h	McGill University	Pan-Canadian Genome Library (PCGL)	\$1,900,000	\$1,900,000
Other	Health	DNASTack	DNASTack	Demonstrating Analytics Integration with the Pan-Canadian Genome Library (PCGL)	\$200,000	\$200,000

eDNA SURVEILLANCE INITIATIVE

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Atlantic	Environment	Gill, Kim	Prince Edward Island Marine Science Organization	Development of eDNA Techniques for MSX and Dermo Surveillance	\$805,867	\$400,000
Genome Atlantic	Environment	Gill, Kim	Prince Edward Island Marine Science Organization	Port Baseline Biodiversity Project	\$204,910	\$75,000
Genome Alberta	Environment	Harrison, Jori Cobb, Tyler	Innotech Alberta University of Alberta	Tailgate eDNA Sequencing for Near-Real-Time Biodiversity Monitoring	\$880,500	\$237,500
Genome Alberta	Environment	Parkins, Michael Hubert, Casey	University of Calgary	Transforming Wastewater-Based Surveillance to an Actionable Public Health Tool for Managing and Mitigating Infections Across a Range of Scales	\$790,500	\$237,500
Genome British Columbia	Health	Gill, Erin Alatini, Mathieya	Simon Fraser University One Yukon Coalition	ChùNet, Enabling a Knowledge Sharing Network - Learning from Water and the Life it Carries	\$1,193,000	\$475,000
Genome Prairie	Health	Cameron, Andrew Ruzzini, Tony	University of Regina University of Saskatchewan	One Health Surveillance for Antimicrobial Resistance and Emerging Pathogens by Targeted Metagenomics at Human-Livestock-Environment Interfaces	\$1,835,053	\$475,000
Génome Québec	Environment	Langlois, Valérie Asselin, Hugo	Institut national de la recherche scientifique Université du Québec	Biodiversity: Assessing eDNA as an Aid to Surveillance (BADAS)	\$960,000	\$475,000
Ontario Genomics	Health	Delatolla, Robert	University of Ottawa	One Health Surveillance of Emergent and Climate Change Health Threats in Southern and Northern, Remote and Isolated First Nations	\$475,000	\$237,500

eDNA SURVEILLANCE INITIATIVE

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Environment	Goodridge, Lawrence Perreault, Melissa	University of Guelph	One Health Approach to Surveillance of Antimicrobial Resistance and Emerging Climate-Related Health Threats using eDNA and eRNA Tools	\$506,219	\$236,681
Genome Atlantic	Environment	Gagnon, Graham Fuller, Megan	Dalhousie University	First Nations-Led Microbial Water Safety: From Source Water Protection to Wastewater Surveillances	\$379,848	\$379,848
Genome Prairie	Environment	Collins, Eric	University of Manitoba	PrairieDNA: Prairies North Environmental DNA Monitoring Network	\$876,800	\$380,000
Genome British Columbia	Health	Brinkman, Fiona Griffiths, Emma	Simon Fraser University	iMicroSeq: Integrated, Inclusive Resources Supporting Environmental Sequence Data	\$1,696,674	\$500,000

Leading-edge technology

CORE OPERATIONS SUPPORT FOR TECHNOLOGY PLATFORMS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome British Columbia	All	Marra, Marco Jones, Steven Nislow, Corey Hirst, Martin	BC Cancer Agency Genome Sciences Centre	BC Cancer Agency Genome Sciences Centre Genomics Technology Platform	\$9,090,202	\$9,090,202
Ontario Genomics	All	Awadalla, Philip Bartlett, John Pugh, Trevor Simpson, Jared Stein, Lincoln	Ontario Institute for Cancer Research	Canadian Data Integration Centre	\$6,136,306	\$6,136,306
Ontario Genomics	All	Scherer, Stephen Strug, Lisa	The Hospital for Sick Children	The Centre for Applied Genomics	\$8,888,251	\$8,888,251

Ontario Genomics	All	Wrana, Jeff Gingras, Anne-Claude	Lunenfeld-Tanenbaum Research Institute Sinai Health System	Network Biology Collaborative Centre	\$4,838,812	\$4,838,812
Ontario Genomics Génome Québec	All	Justice, Monica Vidal, Sylvia	The Hospital for Sick Children McGill University	The Centre for Phenogenomics	\$6,046,189	\$6,046,189

DISRUPTIVE INNOVATION IN GENOMICS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Health	Stagljar, Igor	The University of Toronto	Interactome Mapping of Disease-Related Proteins Using Split Intein-Mediated Protein Ligation (SIMPL)	\$2,223,117	\$741,039
Ontario Genomics	Health	Wheeler, Aaron Kolomietz, Elena Chitayat, David	The University of Toronto Sinai Health Systems	Development of a Digital Microfluidic Platform to Identify and Target Single Cells from a Heterogeneous Cell Population for lysis in an Ultra-Low Volume for Non-Invasive Prenatal Diagnosis	\$3,002,970	\$1,000,000

GENOMIC FACILITY TECHNOLOGY DEVELOPMENT

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Alberta	All	Wakarchuk, Warren	University of Alberta	GlycoNet Integrated Services (GIS)	\$1,000,000	\$1,000,000
Genome Alberta	All	Wishart, David Liang, Li Borchers, Christopher	University of Alberta McGill University	The Metabolomics Innovation Centre	\$1,000,000	\$1,000,000
Ontario Genomics	All	Hébert, Paul	University of Guelph	The Centre for Biodiversity Genomics (CBG)	\$1,000,000	\$1,000,000
Ontario Genomics	All	Scherer, Stephen W. Strug, Lisa Jones, Stevens Ragoussis, Ioannis	The Hospital for Sick Children BC Cancer Research Centre McGill University	CGEn	\$3,333,333	\$3,000,000

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Atlantic	Environment	Hubert, Casey Lemieux, Julie	University of Calgary Triple Point Resources	De-Risking Underground Energy Storage in Atlantic Canada Through Deep Biosphere Genomics	\$896,672	\$298,849
Genome Atlantic	Agriculture	Percival, David Wood, Graham	Dalhousie University Bragg Lumber Inc.	Microbiome-Based Design of Microbial Consortia to Mitigate Stem Blight and Improve Drought Resilience in Wild Blueberry Agroecosystems	\$330,240	\$110,000
Genome Atlantic	Agriculture	Istvanova, Zuzana Lo, Louis	The Verschuren Centre Biofect Innovations Inc.	Precision Fermentation of Brazzein: Enhancing Biosynthesis Efficiency and Optimizing Scale-Up Parameters for Commercialization	\$1,683,404	\$488,685
Genome Alberta	Health	Harrison, Joe Pormohammad, Ali	University of Calgary MHCombiotic Inc.	Genomics-Guided Clinical Utility Assessment of ComBatic: A Broad-Spectrum Antimicrobial Wound Care Innovation for Biofilm-Associated Chronic Wounds and AMR Prevention	\$767,340	\$239,540
Genome Alberta	Health	Wishart, David Durant, Galina	University of Alberta Metabolomix Inc.	Development and Commercialization of QUANTEX-600: A Ready-To-Use Kit for High-Precision Quantitative Exposome Metabolomics	\$449,999	\$149,106
Genome Alberta	Agriculture	Yeaman, Sam Skori, Logan	University of Calgary AgGene Inc.	Identifying Genetic Traits for Abiotic Stress Resilience During Canola Reproduction	\$719,170	\$232,140
Genome Alberta	Health	Yeo, Caitlin Bathe, Oliver	University of Calgary Qualisure Diagnostics	Clinical Utility of Thyroid GuidePx (R): An Alberta-Led Genomic Innovation in Thyroid Cancer Care	\$1,216,043	\$249,476

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome British Columbia	Health	Bally, Marcel Juang, Lih	BC Cancer SeraGene Therapeutics Inc.	A First-in-Class Dual-Function siRNA to Address Limitations of Anticoagulants in Thrombotic Disease	\$885,784	\$295,280
Genome British Columbia	Health	Tang, Patrick Qadir, Mohammed	University of British Columbia Fusion Genomics	Targeted Metagenomics for Enhanced Infectious Disease Diagnosis	\$1,211,628	\$295,280
Genome British Columbia	Health	Zandstra, Peter MacLean, Glenn	University of British Columbia Apiary Therapeutics	Optimized Production of Immune Cells as Advanced Delivery Vehicles for Protein Therapeutics	\$909,509	\$302,123
Genome Prairie	Health	Freywald, Andrew Thomas, Roshan	University of Saskatchewan Oncoforma Biotechnologies Inc.	OncoForma: A Functional Precision Oncology Platform to End the Guesswork in Cancer Treatment	\$1,089,348	\$299,250
Genome Prairie	Environment	McKenna, Sean Gussakovsky, Danny	University of Manitoba White Otter Biotech	Genomic Decision Support Tools for Responsible Resource Development	\$1,736,546	\$300,000
Genome Prairie	Agriculture	Sharpe, Andrew Kulkarni, Manoj	University of Saskatchewan Tuberosum Technologies Inc.	Developing Genomic Selection Platform for Little Potatoes Towards Improving Yield and Tuber Quality Traits	\$890,584	\$264,520
Génome Québec	Agriculture	George, Saji Samsatly, Jamil	McGill University BioSun Products Inc.	Improving Cannabis Resilience and Quality Using Bacteria-Based Biostimulants	\$762,521	\$253,862
Génome Québec	Agriculture	McGraw, Serge Vigneault, Christian	Centre Hospitalier Universitaire Sainte-Justine Boviteq	Molecular Markers for Healthy Calves: Optimizing IVF Conditions with Epigenetic Screening	\$1,032,021	\$282,687
Génome Québec	Health	Lefrançois, Philippe Neil, Kevin	Sir Mortimer B. Davis-Jewish General Hospital TATUM Bioscience	IMMUpredict: A Platform for Intratumoral Vaccination of Skin Cancers	\$600,000	\$200,000

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Génome Québec	Health	Stratton, Jo Anne Zimmer, Mike	Institut-Hôpital neurologique de Montréal RNA4RARE Therapeutics Inc.	Towards the Commercialization of an Omics-Guided RNA-Based Therapy for Neurofibromatosis	\$900,000	\$171,011
Ontario Genomics	Health	Jackson, Hartland Campbell, Kieran	Sinai Health Systems Focai Bio	Quantification and Prediction of Drug Distribution in Tissues for Next-Generation Targeted Therapeutics	\$745,119	\$222,565
Ontario Genomics	Environment	Lawson, Christopher Bowers, Connor	The University of Toronto SymBL Innovations Inc	Genomics-Driven Upcycling of Food Waste to Medium-Chain Fatty Acids Using Engineered Anaerobic Consortia	\$705,156	\$222,578
Ontario Genomics	Health	Robertson, Janice Shenouda, Marc	The University of Toronto Neuropeutics Inc.	Small Molecule Preventing and Reversing TDP-43 Protein Aggregation as Therapeutic for Amyotrophic Lateral Sclerosis	\$882,166	\$222,578
Ontario Genomics	Health	Sadikovic, Bekim Sinai, Dan	London Health Sciences Centre Research Inc. Episign Inc.	Synthetic Reference Epigenomics: Building a Secure Cloud Framework for Scalable Rare Disease Diagnostics	\$691,146	\$222,578
Genome Atlantic	Health	Martinez, Victor Buske, Orion	IWK Health Centre PhenoTips	SmartRequisition: Scalable Genomic Test Requisitions	\$5,428,690	\$1,804,350
Genome British Columbia	Health	Jones, Steven Wong, June	Canada's Michael Smith Genome Sciences Centre Genetrack Biolabs Inc.	OncoTrace DX: Commercialization of a Turnkey Precision Oncology Platform Featuring Matched Tumor- Normal WES, Real-Time AI-Driven Interpretation, and Clinic-Ready Test Kits for Scalable Deployment	\$5,758,671	\$1,914,925

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome British Columbia	Health	Manges, Anne Chorlton, Samuel	University of British Columbia BugSeq Bioinformatics Inc.	Rapid Agnostic Pathogen Identification using Metagenomic Next-Generation Sequencing (RAPID-mNGS)	\$2,546,756	\$847,565
Genome British Columbia	Health	Levings, Megan Tam, Chris	University of British Columbia Integrated Nanotherapeutics	Validation and Process Development Scale Up of a Tolerogenic mRNA/ LNP Therapeutic	\$6,000,000	\$2,000,000
Genome British Columbia	Agriculture	Punja, Zamir Flynn, Mallory J.	Simon Fraser University Insporos Technologies Inc.	High-Resolution Seed Diagnostics for Tomato Brown Rugose Fruit Virus (ToBRFV) Resistance and Infection via Integrated Omics	\$4,441,833	\$1,480,396
Genome British Columbia	Health	Yong, Paul Williamson, Laura	University of British Columbia AbCellera	Identification and Validation of Antibody Therapeutic Targets for Development in Endometriosis	\$3,399,600	\$800,000
Génome Québec	Agriculture	Belzile, François Létourneau, Alain	Université Laval Prograin Inc.	GenoPhAI: Combining Genomics, Phenomics and Artificial Intelligence to Enable Data-Driven Breeding in Soybean	\$2,936,000	\$770,000
Génome Québec	Agriculture	Torkamaneh, Davoud Mouhad, Sabri	Université Laval Aplantex	SpectraLens: Intelligent Screening for High-Throughput Biotransformation in Engineered Biofactories	\$2,205,117	\$735,039
Ontario Genomics	Health	Angers, Stephane Stone, Tracy	The University of Toronto ProteinQure	A Peptide-Directed siRNA Delivery Platform for Glioblastoma Multiforme: Targeting Genes Driving Treatment Resistance	\$2,545,768	\$848,393
Ontario Genomics	Health	Edgell, David Stead, Brent	University of Western Ontario Specific Biologics Inc.	ONTARIAN: bespOke TevCas9 geNe ediTors enABled by diRected evolution and mAchine learNing	\$1,874,621	\$620,121

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Environment	Edwards, Elizabeth A. Peters, Rachel	The University of Toronto Federated Co-operatives Limited	A Novel Approach for Petroleum Pollution: In Situ Anaerobic Biodegradation	\$900,034	\$300,004
Ontario Genomics	Agriculture	Goodridge, Lawrence Guri, Anilda	University of Guelph Gay Lea Foods Co-operative Limited	Optimization of the Nanopore-Optimized Mobile Analysis for Diversity (NOMAD) System for Analysis of Dairy Product Quality	\$2,189,276	\$696,892
Ontario Genomics	Agriculture	Miglior, Filippo Malchiodi, Francesca	University of Guelph Semex Alliance	Future-Proofing the Canadian Dairy Herd: A New Genomic Breeding Tool to Enhance Climate Resiliency	\$2,028,588	\$340,050
Genome Atlantic	Fisheries	Moore, Jean-Sébastien Mallet, André	Université Laval L'Étang Ruisseau Bar Ltée	Accelerating the Development of MSX-Resistant Oysters in Eastern Canada	\$3,137,407	\$1,047,600
Genome Alberta	Health	Lewis, John Coros, Colin	University of Alberta Nanostics Inc	Clinical Utility of ClarityDX Prostate for Widespread Public Adoption in Canada	\$3,845,559	\$1,248,504
Genome British Columbia	Health	Laksman, Zachary Willerth, Stephanie Michelle	University of British Columbia Axolotl Biosciences	Development of 3D-Printed Cardiac Organoids for -Omics Applied to Personalized Medicine	\$900,000	\$300,000
Génome Québec	Health	Borchers, Christoph Zahedi, Rene Popp, Robert	McGill University University of Manitoba MRM Proteomics	SysQuan: Transforming Biomedical and Clinical Research through Enabling Proteome-Wide Absolute Quantitation of the Human Proteome	\$6,468,398	\$1,998,775
Ontario Genomics	Health	Jarvi, Keith Mullen, Brendan	Sinai Health Systems FlowLabs Medical Laboratory	Prostate Cancer Predict: Reducing the Need for Prostate Biopsies by Predicting the Risks of High-Grade Prostrate Cancer (HGPrCa)	\$3,334,267	\$1,108,819

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Génome Québec	Health	Petropoulos, Sophie Grushcow, Jeremy	Université de Montréal Juniper Genomics	Whole Genome Embryo Sequencing Workflow for Improved IVF Outcomes	\$5,596,192	\$1,841,449
Génome Québec	Health	Tremblay, Michel Langlais, David Laneuville, Pierre	McGill University McGill University Health Centre	Establishing Therapeutic Cord Blood Derived NK Cells for Hear-to-Treat Cancers through Omics-based Selection and Pharmacological Activators	\$5,845,337	\$1,600,200
Génome Québec	Environment	Waldispühl, Jérôme Bélanger, Max	McGill University Gearbox Studio	Crowdsourcing the Analysis of Metagenomic Environmental Data for Antimicrobial Resistant Genes through a AAA Video Game	\$4,440,406	\$1,302,373
Ontario Genomics	Health	Wright, Gerard Brown, Eric	McMaster University Kapoose Creek	A Synthetic Biology Platform to Support Fungal Drug Discovery	\$2,220,667	\$712,423
Génome Québec	Agriculture	Giovenazzo, Pierre Maucourt, Ségolène Rousseau, Andrée	Université Laval Centre de recherche en sciences animales de Deschambault	Apiomic, Honeybee Breeding using Genomics	\$3,192,229	\$1,039,814
Ontario Genomics	Health	Pugh, Trevor Racher, Hillary	Princess Margaret Cancer Center - University Health Network Dynacare	Streamlined Care for Canadians with Mismatch Repair Deficient Cancers through Full-Service Genetic and Epigenetic DNA Sequencing	\$747,643	\$247,332
Ontario Genomics	Health	Shlien, Adam Dickson, Brendan	The Hospital for Sick Children Mount Sinai Hospital - Sinai Health Systems	Advancing Patient Care in Oncology: Integrating Multiscale Transcriptomics for Sarcoma Classification, and Beyond	\$6,000,000	\$2,000,000

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome British Columbia	Health	Keown, Paul Liwski, Robert	University of British Columbia Canadian Blood Services	A National Prospective Epitope-Compatibility Matching Program for Canadian Renal Transplant Patients	\$5,870,127	\$1,941,251
Génome Québec	Agriculture	George, Saji Samsatly, Jamil	McGill University BioSun Products Inc.	Nano-Enabled Biostimulant for Sustainable Agriculture: Optimizing Scale-Up Parameters through Genomic Approaches for Commercialization	\$916,787	\$300,238
Ontario Genomics	Health	Sadikovic, Bekim Porecha, Rishi	Lawson Health Research Institute/ Western University Illumina	EpiSign: Health System Impact Assessment and Expanding Clinical Utilization of Epi/ Genomic Testing in Rare Diseases and Beyond	\$7,449,843	\$1,999,978
Ontario Genomics	Health	Haiibe-Kains, Benjamin Pugh, Trevor Dancey, Janet	Princess Margaret Cancer Center - University Health Network Canadian Cancer Clinical Trials Network (3CTN)	Improving Patient Matching to Therapy (PMATCH): Digital Linkage of Preclinical Data to Guide Precision Oncology	\$1,800,000	\$600,000
Génome Québec	Health	Sauvageau, Guy Marinier, Anne	Institut de recherche en immunologie et en cancérologie - Université de Montréal RejuvenRX	Development of a Novel Cyclin K Degradar of High-Risk AML Patients and Associated Genomic Features	\$6,000,000	\$2,000,000
Génome Québec	Agriculture	Robert, Claude Cameron, Johanne	Université Laval Société des éleveurs de moutons de race pure du Québec (SEMRPQ)	Developing the Canadian Sheep Production Using Genomics	\$2,140,769	\$695,750
Génome Québec	Health	Hamet, Pavel Tremblay, Johanne	Université de Montréal OPTITHERA	Predict to Prevent: A Novel Genomic-Derived Score to Improve the Prognostic of T2 Diabetes Patients at High Risk of Complications	\$12,827,735	\$2,000,000

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome British Columbia	Health	Prystajec, Natalie McVea, David Knox, Natalie Henry, Bonnie	The University of British Columbia British Columbia Centre for Disease Control National Microbiology Laboratory, PHAC BC Ministry of Health	Surveillance Alert for Fast Epidemiology Genomics and Unified Agile Response to Disease (SAFEGUARD) Against Respiratory Viruses Using Wastewater Surveillance	\$6,056,973	\$2,000,000
Genome Atlantic	Fisheries	Filgueira, Ramon Hori, Tiago	Dalhousie University Atlantic Aqua Farms Ltd.	Triploid Mussel Genomics Program	\$3,424,281	\$1,113,869
Ontario Genomics	Health	Mahadevan, Radhakrishnan Olivier, Waldemar	The University of Toronto Mesto-Outotec	Developing Novel Bioleaching Process for Ni Recovery from Pyrrhotite Streams	\$6,386,490	\$1,995,074
Ontario Genomics	Health	Awadalla, Phillip McLaughlin, John Dummer, Trevor Hartman, Anne-Renee	Ontario Institute for Cancer Research Canadian Partnership for Tomorrow's Health (CanPath) Adela	Enabling Personalized Genomics in Health with the CanPath Data Safe Haven	\$8,332,826	\$2,000,000
Genome Prairie	Health	Alexander, John Christianson, Sara Reimer, Aleisha	University of Manitoba National Microbiology Laboratory, PHAC	Development and Clinical Implementation of an Omics Assay for the Diagnosis and Treatment of Helicobacter Pylori	\$1,655,505	\$400,152
Genome Prairie	Health	DeCoteau, John Kinloch, Marilyn	University of Saskatchewan Saskatchewan Health Authority	Clinical Implementation of Oncogenomic Testing and Synoptic Reporting for Improved Ovarian Cancer Patient Care in Saskatchewan	\$3,601,782	\$1,101,792
Genome British Columbia	Health	Jones, Steven Lansdorp, Peter Schrader, Kasmintan	The University of British Columbia BC Cancer	Parent-Of-Origin-Aware Genomic Analysis	\$6,040,300	\$1,999,940
Genome British Columbia	Health	Friedman, Jan Ivany, Craig	The University of British Columbia Provincial Health Services Authority	RapidOmics 2.0: Long-read Genome Sequencing for Urgent Genetic Disease Diagnosis	\$3,583,291	\$1,194,367

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Agriculture	Grbic, Vojislava Narva, Ken Coristine, Aaron	University of Western Ontario GreenLight Biosciences, Inc. Ontario Greenhouse Vegetable Growers	Biopesticide with New Modes of Action for Control of Highly Polyphagous Mite Agricultural Pests	\$4,087,687	\$1,362,437
Genome Alberta	Agriculture	Santamaria, Pere Cowan, Jord	University of Calgary Parvus Therapeutics	Transcriptional and Epigenetic Events Underpinning Navacim-Induced TR1 Cell Formation and Expansion	\$2,880,000	\$960,000
Qénome Québec	Agriculture	Basu, Niladri Dalton, Rebecca	McGill University Environment and Climate Change Canada	Validation of the Use of the EcoToxChip Test System for Regulatory Decision Making	\$4,677,943	\$1,483,071
Génome Québec	Agriculture	Landry, Christian Dufresne, Phillippe	Université Laval Le Laboratoire de santé publique du Québec (LSPQ - INSPQ)	Genomics Tools for the Prediction of Antifungal Resistance in Clinical Samples	\$3,360,546	\$786,030
Génome Québec	Agriculture	Comte, Jérôme Levesque, Roger Verreault, Daniel	Université Laval Ministère de l'Environnement et de la Lutte contre les changements climatiques, Québec	RosHAB: Rapid on-site Detection of Harmful Algal Blooms	\$5,400,000	\$1,800,000
Genome Alberta	Health	Hubert, Casey Alexander, Alex	University of Calgary Alberta Health	Genomic Testing of Wastewater to Promote Public Health and Safeguard Economic Performance	\$6,000,001	\$1,999,998
Génome Québec	Health	Borchers, Christoph Zahedi, Renée	McGill University MRM Proteomics	MutaQuant: A Powerful Proteogenomic Phenotyping Tool for Precision Medicine	\$3,029,985	\$1,008,522
Genome Prairie	Agriculture	Adams, Gregg Shury, Todd	University of Saskatchewan Parks Canada	Bison Integrated Genomics (BIG)	\$5,096,909	\$1,664,383

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Génome Québec	Forestry	Bousquet, Jean Lenz, Patrick	Université Laval Natural Resources Canada	FastTRAC2: Fast Tests for Rating and Amelioration of Conifers 2	\$6,143,852	\$2,000,000
Génome Québec	Agriculture	Pilote, Régis Azar, Christian	Agrinova Sollio Groupe Coopératif	Genomics of Milling Oat Breeding and Selection	\$1,823,860	\$585,346
Ontario Genomics	Health	Hawkins, Cynthia Tabori, Uri Pollett, Aaron Somers, Gino	The Hospital for Sick Children Mount Sinai Hospital	Lowpass Genomic Instability Characterization as a Comprehensive Cancer and Germline Diagnostic Assay	\$2,774,310	\$899,998
Genome Atlantic	Fisheries	Fast, Mark Frisch, Kathleen Hewison, Tim	University of Prince Edward Island Cermaq Canada Grieg Seafood	Complex Gill Disease Initiative (CGDI)	\$4,690,770	\$1,537,846
Genome Prairie	Health	Rockman-Greenberg, Cheryl Topp, Adam	University of Manitoba Shared Health	Canadian Prairie Metabolic Network	\$7,586,561	\$2,495,916
Génome Québec	Agriculture	Belzile, François Cowan, Josh	Université Laval Canadian Field Crop Research Alliance Grain Farmers of Ontario	Development and Implementation of a Toolkit for Genomics-Assisted Breeding in Soybean	\$7,001,050	\$2,000,000
Ontario Genomics	Health	Liu, Peter Ziegler, André	University of Ottawa Roche Diagnostics International Ltd.	Cardiovascular Biomarker Translation 2 (CBT2) – Atrial Fibrillation	\$5,955,141	\$1,983,487
Genome Atlantic	Fisheries	Garber, Amber Guest, Dean	Huntsman Marine Science Centre Mowi Canada East	Advancing Commercial Performance of North America Origin Atlantic Salmon through Integration of Genomic Selection	\$4,679,944	\$1,398,095

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics	Environment	Ensminger, Ingo Isabel, Nathalie	The University of Toronto Natural Resources Canada	Fast Track Diagnosis of Stress, Disease, Phenology and Growth - Drone-Based High-Throughput Field Phenotyping for Genome Assisted Tree Breeding and Selection (FastPheno)	\$4,744,502	\$1,581,501
Ontario Genomics	Health	McPherson, Peter Raina, Chetan	McGill University YCharOS Inc.	Antibody Characterization for Open Science – Towards Characterized Antibodies for the Human Proteome	\$3,979,175	\$959,982
Genome British Columbia	Agriculture	Poojari, Sudarsana Zhang, Xuekui Rott, Mike Schenck, Bill	Brock University University of Victoria Canadian Food Inspection Agency Canadian Grapevine Certification Network	CLEAn pLAnt extractioN SEquencing Diagnostics (CLEANSED) for Clean Grapevines in Canada	\$6,236,193	\$2,000,000
Genome British Columbia	Agriculture	Rieseberg, Lorne Baute, Greg	The University of British Columbia	Fast-Track Breeding of Powdery Mildew-Resistant Cannabis	\$4,265,446	\$1,421,673
Génome Québec	Agriculture	Bélanger, Richard Vivancos, Julien	Université Laval Ministère de l'Agriculture, des Pêcheries et de l'Alimentation du Québec	Development and Validation of a Genomic-Based Diagnostic Tool of the Virulence Profile of Phytophthora Sojae, a Major Pathogen of Soybean	\$3,259,878	\$956,081
Génome Québec	Environment	Sunday, Jennifer Rubidge, Emily Stanley, Ryan	McGill University Fisheries and Oceans Canada	Optimizing the eDNA Approach to Monitor Biodiversity in Canada's Marine Protected Areas	\$757,409	\$242,100
Genome Atlantic	Health	Bedard, Karen Vandersteen, Anthony Brock, Jo Ann Dyack, Sarah	Dalhousie University IWK Health Centre	Implementation of Clinical Exomes in a Pre- and Peri-Natal Setting	\$6,360,611	\$2,080,695
Génome Québec	Agriculture	Martin, Vincent Pouliot, Michel	Concordia University Agropur Cooperative	Bioprocess Development for Lactose Valorisation	\$1,950,000	\$650,000

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Ontario Genomics Génome Québec	Health	Goodridge, Lawrence Levesque, Roger Landgraff, Chrystal	University of Guelph Université Laval Public Health Agency of Canada	Stopping Enteric Illnesses Early (Sentinel)	\$6,490,662	\$1,907,690
Ontario Genomics	Energy	Rehmann, Lars	University of Western Ontario World Energy Hamilton	Strain Development for Butanol Process Addition to Existing Biodiesel Plants	\$796,745	\$265,499
Genome Alberta	Health	Bernier, François O'Hara, Carolyn	University of Calgary Alberta Precision Laboratories	TIGeR: Translational Implementation of Genomics for Rare Diseases	\$6,246,990	\$2,150,334
Genome British Columbia	Health	Lehman, Anna Ivany, Craig	The University of British Columbia Provincial Health Services Authority	Implementation of Diagnostic Whole Genome Sequencing for Rare Diseases in British Columbia	\$9,662,785	\$2,499,086
Génome Québec	Health	Michaud, Jacques Ouellet, Denis	Centre Hospitalier Universitaire Sainte-Justine Ministère de la Santé et des Service sociaux	Rapid Whole-Genome Sequencing in Acute Care Neonates and Infants	\$8,107,867	\$2,500,000
Ontario Genomics	Health	Cowen, Leah Jaikaran, Dominic	The University of Toronto Bright Angel Therapeutics	Targeting Fungal Stress Responses to Provide First-in-Class Treatment for Drug Resistant Fungal Pathogens	\$5,516,034	\$1,986,029
Génome Québec	Health	Waldispühl, Jérôme Szantner, Attila	McGill University Massively Multiplayer Online Science	Crowdsourcing Sequence Alignments in a AAA Game for Microbiome Research	\$2,953,319	\$803,250
Ontario Genomics	Health	Boycott, Kym Somerville, Martin Sarta, Neeta	Children's Hospital of Eastern Ontario Research Institute The Hospital for Sick Children Ontario Ministry of Health	Optimization and Implementation of a Clinical Genome-Wide Sequencing Service for Rare Disease Diagnosis in Ontario	\$7,850,000	\$2,500,000

GENOMIC APPLICATIONS PARTNERSHIP PROGRAM

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Génome Québec	Agriculture	Labrie, Steve Fraud, Sebastian	Université Laval General Mills	Genomic-Based Approach to Optimize the Development of Texturizing Bacterial Strains in Yogurt	\$1,170,675	\$390,225
Ontario Genomics	Health	Moffat, Jason Singh, Sheila	The University of Toronto Century Therapeutics	Systematic Evaluation and Optimization of Immune-Targeting Modalities for GBM and Brain Metastases	\$4,483,118	\$1,345,100
Genome Atlantic	Fisheries	Bernatchez, Lewis Mallet, André	Université Laval L'Étang Ruisseau Bar Ltd	Genomics for Developing the First Canadian Production Ready Strain of Selectively Bred Eastern Oyster	\$3,806,291	\$1,249,924
Génome Québec	Health	Borchers, Christoph Spatz, Alan Leduc, Claude	Lady Davis Institute Jewish General Hospital MRM Proteomics Inc.	Developing the Next Generation PD-L1 Assays Using Precision Mass Spectrometry	\$1,449,026	\$478,138
Ontario Genomics	Environment	Edwards, Elizabeth A. Dworatzek, Sandra	The University of Toronto SiREM	Field Validation of Technologies for Anaerobic Benzene and Alkylbenzene Bioremediation	\$2,752,161	\$926,160
Ontario Genomics	Health	Surette, Michael Magarvey, Nathan Haigh, Andrew	McMaster University Adapsyn Bioscience Inc.	Applying the Adapsyn Genomics Platform to the Identification, Isolation, and Characterization of Immune Modulators from the Human Microbiome	\$6,034,102	\$1,990,459
Ontario Genomics	Environment	Mahadevan, Radhakrishnan Dugar, Deepak	The University of Toronto Visolis Inc.	Genomics Driven Engineering of Hosts for Bio-Nylon	\$5,700,000	\$1,900,000

GENOMICS IN SOCIETY INTERDISCIPLINARY RESEARCH TEAMS

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome British Columbia Ontario Genomics	Agriculture	Regier, Dean A. Bubela, Tania Hanna, Timothy	BC Cancer Research Simon Fraser University Queen's University	Canadian Network for Learning Healthcare Systems and Cost Effective 'Omics Innovation	\$2,628,837	\$1,000,000
Genome Alberta Ontario Genomics	Health	Murray, Maribeth S. Pulsifer, Peter	University of Calgary Carleton University	The Role of Genomics in Fostering and Supporting Arctic Biodiversity: Implications for Wildlife Management, Policy and Indigenous Food Security	\$1,879,203	\$932,330

CLIMATE SMART AGRICULTURE AND FOOD SYSTEMS INITIATIVE

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Alberta	Agriculture	Fitzsimmons, Carolyn Cahill, James	University of Alberta Agriculture and Agri-Food Canada University of Saskatchewan	Combining Omic Technology and Grassland Management to Enhance Soil Carbon Sequestration and Reduce Greenhouse Emissions	\$6,230,801	\$2,998,199
Genome Alberta	Agriculture	Samuel, Marcus Kagale, Samuel	University of Calgary National Research Council of Canada	PeaCE (Pea Climate- Efficient): Developing Climate-Resilient, Low Carbon Footprint Field Pea as a Preferred Rotation Crop through Inter-Disciplinary Integration of Genomic Technologies	\$6,883,129	\$2,998,159
Genome British Columbia	Agriculture	Pizzirani, Stefania Newell, Robert	University of the Fraser Valley Royal Roads University	The Social Implications of Agri-Genomics: Ensuring a Just Transition to Climate Resilient Agricultural and Food Systems in Canada	\$2,506,100	\$1,253,043
Genome Prairie	Agriculture	Bennett, Jonathan Asselin, Sean	University of Saskatchewan Agriculture and Agri-Food Canada - Swift Current University of Manitoba	Grassland Genomics for Green House Gas Mitigation (GG4GHG)	\$5,953,556	\$2,826,148
Genome Prairie	Agriculture	Bett, Kristin Pozniak, Curtis	University of Saskatchewan Grain Commission	ACTIVATing Genomics to Accelerate Climate- Smart Cultivars	\$6,000,000	\$3,000,000
Genome Prairie	Agriculture	Oresnik, Ivan diCenzo, George	University of Manitoba Queen's University	Bio-inoculants for the Promotion of Nutrient Use Efficiency and Crop Resiliency in Canadian Agriculture	\$6,445,071	\$3,000,000

CLIMATE SMART AGRICULTURE AND FOOD SYSTEMS INITIATIVE

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Génome Québec	Agriculture	Laur, Joan Hénault-Ethier, Louise	Université de Montréal Institut national de la recherche scientifique	Omics to Close the Loop: Optimized Amendment from Local Agrifood Waste for Carbon Footprint Reduction	\$6,395,706	\$3,000,000
Ontario Genomics	Agriculture	Baes, Christine Miglior, Filippo Gervais, Rachel Stothard, Paul	University of Guelph Université Laval University of Alberta	Leveraging Genomics to Achieve Dairy Net Zero	\$16,196,780	\$2,999,515
Ontario Genomics	Agriculture	Selvaganapathy, P.Ravi Audet, Julie von Massow, Michael Bamji-Mirza, Michelle	McMaster University The University of Toronto University of Guelph Collège La Cité	Omics Guided Technologies for Scalable Production of Cell-Cultivated Meat	\$10,126,027	\$2,964,661
Genome British Columbia	Agriculture	Hsiao, Willian Edwards, Michelle Robert, Claude	McMaster University University of Guelph Université Laval	Climate Smart Data Collaboration Centre	\$4,150,385	\$1,468,351
Ontario Genomics	Agriculture	Shantz, Elizabeth Bowes, Jessica Tout, Nancy Battersby, Lupin	University of Guelph Global Institute for Food Security Simon Fraser University	Agricultural Genomics in Action Centre: Innovation, Implementation and Impact for Climate Smart Agriculture	\$1,638,380	\$760,777

CANADIAN PRECISION HEALTH INITIATIVE

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Genome Atlantic	Health	Allen, Upton Jerome-Majewska, Loydie Dryden, OmiSoore Daniel, Juliet	The Hospital for Sick Children McGill University Dalhousie University McMaster University	Genomic Evidence for Precision Medicine for Selected Chronic Diseases among Black Peoples in Canada	\$18,321,067	\$8,348,875
Genome Alberta	Health	Arnold, Paul Bousman, Chad Dimitropoulos, Gina Zwicker, Jennifer	University of Calgary	Pan-Canadian Initiative Linking Genomic, Environmental and Mental Health Data in Children and Youth (Pan-GEM)	\$10,016,012	\$4,993,989
Genome Alberta	Health	Jickling, Glen Wishart, David	University of Alberta	Genomics of Stroke and Cardiovascular Disease	\$4,741,798	\$2,026,764
Genome British Columbia	Health	Carleton, Bruce Reider, Michael Krajinovic, Maja	University of British Columbia University of Western Ontario Université de Montréal	Longitudinal, Deep-Phenotyped Pediatric Databank of Medical and Drug Therapy Outcomes	\$17,168,141	\$7,486,349
Genome British Columbia	Health	Schrader, Kasmintan Lansdorp, Peter Jones, Stephen	BC Cancer	Enhanced Population Cancer Care through Mainstream Genome Sequencing and Parent-of-Origin Detection	\$11,999,914	\$1,901,444
Genome British Columbia	Health	Tsang, Teresa Lehman, Anna Meredith, Anna Legault, Gabrielle Abolmaesumi, Purang Sing, Anurag	University of British Columbia University of Northern British Columbia	MOSAIC - Multi-Omics and Sonography to Advance Indigenous and Community Cardiovascular Health	\$11,558,892	\$5,736,658
Genome Prairie	Health	Rockman-Greenberg, Cheryl Zovoilis, Athanasios Zwarych, Spencer Turner, Donna	University of Manitoba University of Saskatchewan CancerCare Manitoba	PrairieGen: A Multi-Omics Approach to Advancing Data Integration from Manitoba and Saskatchewan Populations into the PanCanadian Genome Library	\$7,186,736	\$3,413,390

CANADIAN PRECISION HEALTH INITIATIVE

Centre(s)	Sector	Leader(s)	Organization(s)	Title	Total Funding	Genome Canada Contribution
Génome Québec	Health	Gan-Or, Ziv Tetrault, Martine	McGill University Université de Montréal	Neuro Genomics Initiative (NRGI): Cohort Focusing on Neurological Disorders	\$15,225,564	\$7,153,542
Ontario Genomics	Health	Anagnostou, Evdokia Crosbie, Jennifer Scherer, Stephen Gallagher, Louise Vorstman, Jacob Fehlings, Darcy Zemek, Roger Andrade, Danielle	Holland Bloorview Research Institute The Hospital for Sick Children The University of Toronto Children's Hospital of Eastern Ontario Research Institute University Health Network	Precision Health Network for Neurodevelopment, Mental Health and Brain Injury	\$12,513,002	\$6,250,904
Ontario Genomics	Health	Boycott, Kym Marshall, Christian Bernier, François Michaud, Jacques	Children's Hospital of Eastern Ontario Research Institute The Hospital for Sick Children University of Calgary Centre Hospitalier Universitaire Sainte-Justine	Expanding the Use of Genomics to Unravel Rare Diseases: Care4Rare EXPAND	\$20,031,419	\$9,999,595
Ontario Genomics	Health	Kernohan, Kristin Sondheimer, Neal Lacaria, Melanie Barciak, Erika Chakraborty, Pranesh Henderson, Matthew	Children's Hospital of Eastern Ontario Research Institute	INFANT: Identifying at Risk Newborns from the Analysis of NGS Testing	\$12,000,000	\$6,000,000
Ontario Genomics	Health	Scherer, Stephen Mital, Seema Malkin, David Hiraki, Linda Ricciuto, Amanda Costain, Gregory Wang, Yiming Cohn, Ronald	The Hospital for Sick Children	Precision Child Health - Comprehensive Sequencing for Childhood Life-Long Disorders	\$15,430,370	\$7,518,328

Audited financial statements

Genome Canada
Financial Statements
March 31, 2026

Independent Auditor's Report	2 - 4
Financial Statements	
Financial Position	5
Operations	6
Changes in Net Assets	7
Cash Flows	8
Notes to Financial Statements	9 - 15

Independent Auditor's Report

Raymond Chabot
Grant Thornton LLP
City Park Place, Suite 200
1900 City Park Drive
Ottawa, Ontario
K1J 1A3

T 613-236-2211

To the Directors of
Genome Canada

Opinion

We have audited the financial statements of Genome Canada (hereafter "the Corporation"), which comprise the statement of financial position as at March 31, 2026, and the statements of operations, changes in net assets and cash flows for the year then ended, and notes to financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Corporation as at March 31, 2026, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We are independent of the Corporation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of management and those charged with governance for the financial statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Corporation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Corporation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Corporation's financial reporting process.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Corporation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Corporation to cease to continue as a going concern;
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Raymond Chabot Grant Thornton LLP

Chartered Professional Accountants,
Licensed Public Accountants

Ottawa, Canada
June 26, 2026

Genome Canada Financial Position

March 31, 2026

	2026	2025
	\$	\$
ASSETS		
Current		
Cash	3,140,323	1,479,037
Trade and other receivables (Note 4)	140,072	125,084
Prepaid expenses	436,148	489,428
Short-term investments (Note 5)	1,893,781	8,150,660
	<u>5,610,324</u>	10,244,209
Long-term		
Tangible capital assets (Note 6)	146,059	146,077
	<u>5,756,383</u>	<u>10,390,286</u>
LIABILITIES		
Current		
Trade payables and other operating liabilities (Note 7)	981,589	902,932
Deferred contributions - research projects (Note 8)	2,682,032	7,868,440
	<u>3,663,621</u>	8,771,372
Long-term		
Deferred lease inducements	10,543	15,063
Deferred contributions related to tangible capital assets (Note 9)	146,059	146,077
	<u>3,820,223</u>	8,932,512
NET ASSETS		
Internally restricted	1,936,160	1,457,774
	<u>5,756,383</u>	<u>10,390,286</u>

The accompanying notes are an integral part of the financial statements.

On behalf of the Board,

DocuSigned by:
Rob Annan
Rob Annan, President and CEO

DocuSigned by:
Bonnie Schmidt
Bonnie Schmidt, Board Chair

Genome Canada Operations

Year ended March 31, 2026

	<u>2026</u>	<u>2025</u>
	\$	\$
Revenue		
Contributions - Research projects and operating expenditures	98,102,090	70,330,107
Net investment income (Note 3)	478,386	1,073,186
Amortization of deferred contributions related to tangible capital assets (Note 9)	38,786	39,273
	98,619,262	71,442,566
Expenses		
Projects and Genome Centres	91,389,187	64,681,471
Office of the President	1,264,298	815,560
Corporate services	3,608,873	2,930,765
Program management	1,839,732	2,327,296
Amortization of tangible capital assets	38,786	39,273
	98,140,876	70,794,365
Excess of revenues over expenses	478,386	648,201

The accompanying notes are an integral part of the financial statements.

Genome Canada Changes in Net Assets

Year ended March 31, 2026

	2026			2025
	Unrestricted	Internally restricted (Note 10)	Total	Total
	\$	\$	\$	\$
Balance, beginning of year		1,457,774	1,457,774	809,573
Excess of revenues over expenses	478,386		478,386	648,201
Internal restriction (Note 10)	(478,386)	478,386		
Balance, end of year	-	1,936,160	1,936,160	1,457,774

The accompanying notes are an integral part of the financial statements.

Genome Canada Cash Flows

Year ended March 31, 2026

	<u>2026</u>	<u>2025</u>
	\$	\$
OPERATING ACTIVITIES		
Excess of revenues over expenses	478,386	648,201
Non-cash items		
Amortization of tangible capital assets	38,786	39,273
Amortization of deferred lease inducement	(4,520)	(4,518)
Net change in fair value of investments	(206,087)	(550,885)
Amortization of deferred contributions related to tangible capital assets	(38,786)	(39,273)
	267,779	92,798
Changes in working capital items		
Trade and other receivables	(14,988)	293,029
Prepaid expenses	53,280	(145,500)
Trade payables and other operating liabilities	78,657	47,207
Deferred contributions - research projects	(5,147,640)	(36,141,424)
	(5,030,691)	(35,946,688)
Cash flows from operating activities	(4,762,912)	(35,853,890)
INVESTING ACTIVITIES		
Investments	(63,618,471)	(98,827,655)
Disposal of investments	70,081,437	134,348,676
Acquisition of tangible capital assets	(38,768)	(31,017)
Cash flows from investing activities	6,424,198	35,490,004
Net increase (decrease) in cash	1,661,286	(363,886)
Cash, beginning of year	1,479,037	1,842,923
Cash, end of year	3,140,323	1,479,037

The accompanying notes are an integral part of the financial statements.

Genome Canada

Notes to Financial Statements

March 31, 2026

1 - GOVERNING STATUTES

The Corporation was incorporated on February 8, 2000, under the Canada Corporations Act and continued on December 11, 2012. The Corporation is a not-for-profit organization and has the following objectives:

- a) The development and establishment of a co-ordinated strategy for genomics research to enable Canada to become a world leader in areas such as health, agriculture, environment, forestry, fisheries, mining and energy;
- b) The provision of leading-edge technology to researchers in all genomics-related fields through regional Genome Centres across Canada, of which there are currently six, one each in British Columbia, Alberta, the Prairies, Ontario, Quebec and the Atlantic;
- c) The support of large-scale projects of strategic importance to Canada by bringing together industry, government, universities, research hospitals and the public;
- d) The assumption of leadership in the area of ethical, environmental, economic, legal, social and other issues related to genomics research, and the communication of the relative risks, rewards and successes of genomics to the Canada public; and
- e) The encouragement of investment by others in the field of genomics research.

As a not-for-profit organization, the Corporation is not subject to income taxes.

2 - SUMMARY OF ACCOUNTING POLICIES

Basis of presentation

The Corporation's financial statements are prepared in accordance with Canadian accounting standards for not-for-profit organizations.

Accounting estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the amounts recorded in the financial statements and notes to financial statements. These estimates are based on management's best knowledge of current events and actions that the Corporation may undertake in the future. Actual results may differ from these estimates.

Genome Canada
Notes to Financial Statements
 March 31, 2026

2 - SUMMARY OF ACCOUNTING POLICIES (Continued)

Revenue recognition

Contributions and related investment income

The Corporation follows the deferral method of accounting for contributions received from the Government of Canada and related investment income. Under this method, contributions restricted for future period expenses are deferred and are recognized as revenue in the year in which the related expenses are incurred. Restricted contributions for the purchase of capital assets are deferred and amortized to revenue on a declining balance basis at a rate corresponding to the amortization rate for the related capital assets. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Net investment income

Investment transactions are recognized at the transaction date and resulting revenues are recognized in earnings using the accrual basis of accounting.

Interest income is recognized on a time proportion basis.

Changes in fair value are recognized when they occur. Gains or losses on the disposal of investments measured at cost are determined using the average cost method.

Financial assets and liabilities

Initial measurement

Upon initial measurement, the Corporation's financial assets and liabilities are measured at fair value, which, in the case of financial assets or financial liabilities that will be measured subsequently at amortized cost, is increased or decreased by the amount of the related financing fees and transaction costs. The Corporation's financial assets and liabilities from related party transactions are measured at cost.

Subsequent measurement

At each reporting date, the Corporation measures its financial assets and liabilities from transactions not concluded with related parties at amortized cost (including any impairment in the case of financial assets), except for investments in government of Canada treasury bills, mutual funds, provincial/municipal short-term bills and notes and federal bonds which are measured at fair value.

With respect to financial assets measured at amortized cost or using the cost method, the Corporation assesses whether there are any indications of impairment. When there is an indication of impairment, and if the Corporation determines that during the year there was a significant adverse change in the expected timing or amount of future cash flows from a financial asset, it will then recognize a reduction as an impairment loss in earnings. The reversal of a previously recognized impairment loss on a financial asset measured at amortized cost or using the cost method is recognized in earnings in the year the reversal occurs.

Genome Canada
Notes to Financial Statements
 March 31, 2026

2 - SUMMARY OF ACCOUNTING POLICIES (Continued)

Tangible capital assets

Tangible capital assets acquired are recorded at cost.

Amortization

Tangible capital assets are amortized over their estimated useful lives according to the diminishing balance method at the following annual rates:

	<u>Rates</u>
Furniture, fixtures and office equipment	20%
Computers and software	50%

Write-down

When the Corporation recognizes that a tangible capital asset no longer has any long-term service potential, the excess of net carrying amount of the tangible capital asset over its residual value is recognized as an expense in the statement of operations.

Lease inducements

Lease inducements, consisting of free rent and improvement allowances granted to the Corporation for the leased offices, are amortized on a straight-line basis over the term of the lease.

3 - NET INVESTMENT INCOME

	<u>2026</u>	<u>2025</u>
	\$	\$
Investments measured at fair value		
Income from investment funds and changes in fair value of investments	265,634	791,467
Transaction costs	<u>(22,512)</u>	<u>(46,150)</u>
	<u>243,122</u>	<u>745,317</u>
Investments measured at cost		
Interest income	<u>235,264</u>	<u>327,869</u>
	<u>478,386</u>	<u>1,073,186</u>

4 - TRADE AND OTHER RECEIVABLES

	<u>2026</u>	<u>2025</u>
	\$	\$
Trade accounts receivable	19,962	46,550
Indirect taxes receivable	<u>120,110</u>	<u>78,534</u>
	<u>140,072</u>	<u>125,084</u>

Genome Canada
Notes to Financial Statements
 March 31, 2026

5 - SHORT-TERM INVESTMENTS

	2026		2025	
	Cost	Fair market value	Cost	Fair market value
	\$	\$	\$	\$
Cash	12,962	12,962	2,041,168	2,041,168
Government of Canada Treasury bills			3,450,020	3,494,176
Mutual funds			119,363	119,363
Provincial/Municipal short-term bills and notes	756,823	759,955	2,464,000	2,495,953
Federal bonds	1,105,680	1,120,864		
	1,875,465	1,893,781	8,074,551	8,150,660

6 - TANGIBLE CAPITAL ASSETS

	2026		2025
	Cost	Accumulated amortization	Net carrying amount
	\$	\$	\$
Furniture, fixtures and office equipment	390,677	285,358	105,319
Computer and software	74,109	33,369	40,740
	464,786	318,727	146,059

7 - TRADE PAYABLES AND OTHER OPERATING LIABILITIES

Government remittances total \$12,363 as at March 31, 2026 (\$10,336 as at March 31, 2025).

8 - DEFERRED CONTRIBUTIONS - RESEARCH PROJECTS

The Corporation receives contributions from the Government of Canada to be held, invested, administered and disbursed in accordance with the related funding agreement between the Corporation and the Government of Canada.

The Corporation operates under four active Funding Agreements with the Government of Canada. As at March 31, 2026, Innovation, Science and Economic Development Canada (ISED) had committed \$499,455,424 in contributions to the Corporation under these agreements, of which \$290,768,118 has been received. The terms and conditions of these agreements call for remaining contributions to be paid to the Corporation annually, subject to the appropriation by the Parliament, based on the estimated cash requirements for the year. During the year ended March 31, 2026, the Corporation received \$7,700,000 under the agreement dated April 1, 2020 (amended February 17, 2026), \$34,700,000 under the agreement dated April 1, 2022 (amended March 4, 2024), \$24,940,700 under the agreement dated April 1, 2024 and \$25,613,750 under the agreement dated March 15, 2025.

Genome Canada
Notes to Financial Statements
 March 31, 2026

8 - DEFERRED CONTRIBUTIONS - RESEARCH PROJECTS (Continued)

Deferred contributions related to expenses of future years represent unspent externally restricted funding received to date, together with investment revenue earned, for the purpose of providing funds to eligible recipients and paying for operating and capital expenditures in futures years.

	<u>2026</u>	<u>2025</u>
	\$	\$
Balance, beginning of year	7,868,440	43,615,896
Grants received	92,954,450	34,613,668
Amount recognized in operations	(98,102,090)	(70,330,107)
Amount recognized in capital assets	(38,768)	(31,017)
Balance, end of year	<u>2,682,032</u>	<u>7,868,440</u>

9 - DEFERRED CONTRIBUTIONS RELATED TO TANGIBLE CAPITAL ASSETS

Deferred contributions related to capital assets represent restricted contributions with which capital assets were originally purchased.

	<u>2026</u>	<u>2025</u>
	\$	\$
Balance, beginning of year	146,077	154,333
Investments in capital assets	38,768	31,017
Amounts amortized to operations	(38,786)	(39,273)
Balance, end of year	<u>146,059</u>	<u>146,077</u>

10 - NET ASSETS - INTERNALLY RESTRICTED

The Board of Directors initially approved an increase to the internally restricted reserve to \$2,900,000 in June 2024 to cover the cost of a potential wind-down following the end of the Strategic Science Fund. In June 2025, the Board of Directors approved a reduction of this allocation to \$2,800,000. The reserve is funded from the quarterly investment income. During the year, the investment income of \$478,386 was reallocated to the internally restricted reserve.

11 - EMPLOYEE PENSION PLAN

The Corporation maintains, for the benefits of its employees, a defined contribution pension plan. The cost of the plan is recorded in the statement of operations and changes in net assets as it is incurred. The charge for the year totals \$232,155 (\$215,679 as at March 31, 2025).

Genome Canada
Notes to Financial Statements
 March 31, 2026

12 - COMMITMENTS

The Corporation is committed to financing approved research projects, science and technology platforms and Genome Centre operations in accordance with established agreements totalling \$76,522,702. The payments committed for the next three years are \$41,161,838 in 2027, \$24,396,175 in 2028 and \$10,964,689 in 2029.

The Corporation leases its premises and equipment under long-term operating leases, which expire at various dates between March 2027 and May 2028, which call for lease payments of \$505,235. Minimum lease payments for the next three years are \$246,750 in 2027, \$237,657 in 2028 and \$20,828 in 2029.

13 - FINANCIAL RISKS

Credit risk

The Corporation is exposed to credit risk regarding the financial assets recognized on the balance sheet. The Corporation has determined that the financial assets with more credit risk exposure are trade accounts receivable since failure of any of these parties to fulfil their obligations could result in significant financial losses for the Corporation.

Market risk

The Corporation's financial instruments expose it to market risk, in particular, to interest rate risk and other price risk, resulting from its investing activities:

Interest rate risk

The Corporation is exposed to interest rate risk with respect to financial assets bearing fixed interest rates.

The Provincial/Municipal short-term bills and the Federal bonds disclosed in Note 5 bear interest at a fixed rate and the Corporation is, therefore, exposed to the risk of changes in fair value resulting from interest rate fluctuations.

Other price risk

The Corporation is exposed to other price risk due to investments disclosed in Note 5 since changes in market prices could result in changes in the fair value or cash flows of these instruments.

Genome Canada
Notes to Financial Statements
March 31, 2026

13 - FINANCIAL RISKS (Continued)


Liquidity risk

The Corporation's liquidity risk represents the risk that the Corporation could encounter difficulty in meeting obligations associated with its financial liabilities. The Corporation is, therefore, exposed to liquidity risk with respect to all of the financial liabilities recognized on the statement of financial position.

Acknowledgements

Genome Canada gratefully acknowledges the support of the Government of Canada, and specifically Innovation, Science and Economic Development Canada (ISED), the lead investor in our challenge-driven genomics initiatives. This investment supports our focus on mobilizing Canada’s genomics research, innovation, data and talent ecosystem on areas of strategic importance for Canada where genomics can promote a healthier population, a stronger economy and a more sustainable planet.

With funding from



In addition to the diverse project partners who participate in our research initiatives, we collaborate broadly across Canada’s research and innovation ecosystem in program development, delivery and policy dialogue. We wish to acknowledge these strategic partners for their value-add collaboration last year. We are grateful for our ongoing engagement with the research, industry, public and community sectors at home and abroad.

adMare BioInnovations	Canadian Science Policy Centre	Let’s Talk Science
Advancing and Evaluating the Societal Impact of Science (Netherlands)	Canadian Standards Association	Liberty Co
Agriculture and Agri-Food Canada	Centre d’expertise et de services Génome Québec	McGill Genome Centre
Agri-Food Innovation Council	Colleges and Institutes Canada	Mitacs
All of Us Research Program, National Institutes of Health (United States)	Consortium Québécois sur la Découverte du Médicament	National Microbiology Laboratory
American Society of Human Genetics (United States)	CropLife Canada	National Research Council of Canada
ArcticNet	DIGITAL	Natural Sciences and Engineering Research Council
Asia Pacific Foundation of Canada	Digital Research Alliance of Canada	Novo Nordisk Foundation (Denmark)
BioCanRx	DNASTack	NutriAg Ltd
Bioethics Council of Canada	ELIXIR (European Union)	Office of the Chief Science Advisor and Youth Council
BIOTECCanada	Environment and Climate Change Canada	Ontario Institute for Cancer Research
Bloom Burton	European Bioinformatics Institute (United Kingdom)	Organization for Economic Cooperation and Development
CGEn	European Rare Diseases Research Alliance (European Union)	Oxford Nanopore Technologies
Canada Foundation for Innovation	Fisheries and Oceans Canada	PacBio
Canada’s Michael Smith Genome Sciences Centre	Gairdner Foundation	Pan Canadian Genome Library
Canadian Bioinformatics Hub	Genomics Australia (Australia)	Public Health Agency of Canada
Canadian Black Scientists Network	Genomics England (United Kingdom)	Public Policy Forum
Canadian Cancer Research Alliance	Genomics Research and Development Initiative	Red Rabbit Learning Services Inc.
Canadian Chamber of Commerce	Global Affairs Canada	Signal49 Research
Canadian College for Medical Geneticists	Global Alliance for Genomics and Health	Social Sciences and Humanities Research Council
Canadian Drug Agency	Global Biodata Coalition	Society for Canadian Women in Science and Technology
Canadian Food Innovation Network	Global Genomic Medicine Consortium	Speakers Bureau Canada
Canadian Forum for Social Innovation	Health Canada	Standards Council of Canada
Canadian Institute for Advanced Research	ICPerMed International Consortium (European Union)	Stem Cell Network
Canadian Institute for Health Information	Illumina	Terry Fox Research Institute
Canadian Institutes of Health Research (CIHR)	Indigenous Works	Tharris Inc.
CIHR Institute of Cancer Research	Institute for Research on Public Policy	The Centre for Applied Genomics
CIHR Institute for Genetics	Institute on Governance	Universities Canada
Canadian Organization for Rare Disorders	International Development Research Centre	VITAL
Canadian Public Health Laboratory Network	International Rare Disease Research Consortium	Wellcome Trust (United Kingdom)
Canadian Rare Disease Network		

Abbreviations used in the report

CBH	Canadian Bioinformatics Hub
CGS	Canadian Genomics Strategy
CIFOR	Center for International Forestry Research
CIHR	Canadian Institutes of Health Research
CPHI	Canadian Precision Health Initiative
CSAFS	Climate-Smart Agriculture and Food Systems
GAPP	Genomic Applications Partnership Program
IDEA	Inclusion, Diversity, Equity and Accessibility
ITRE	Indigenous Truth, Reconciliation and Engagement
MUHC	McGill University Health Centre
R&D	research and development
SSF	Strategic Science Fund



150 Metcalfe Street
Suite 2100
Ottawa, ON K2P 1P1

genomecanada.ca

 genome-canada

 genomecanada

 genomecanada.ca

 @genomecanada

Annual report design by  Character Creative